Republic of Moldova

Market Segmentation Analysis for Modern Contraceptives in the Republic of Moldova

Prepared by: Dr. Godfrey Walker, Consultant
This document was produced with the support of UNFPA, United Nations Population Fund in Moldova, and does not necessarily represent the views of UNFPA, the United Nations or any of its affiliated organizations.
## Contents

Figures ................................................................................................................................. ii
Tables................................................................................................................................... iii
Acronyms ............................................................................................................................... iv
Acknowledgements .............................................................................................................. vi
Executive Summary ............................................................................................................. 1
  Introduction ......................................................................................................................... 1
  Recommendations on specific issues concerned with provision of modern contraceptives .... 2
  Activities which UNFPA could consider, supporting the Government to strengthen family planning .......................................................... 3
Market Segmentation Analysis for Modern Contraceptives in the Republic of Moldova .... 4
Terms of Reference for the Consultancy ............................................................................... 4
Methods ............................................................................................................................... 5
Background ........................................................................................................................... 5
  Introduction - Country Context ........................................................................................... 5
  Poverty and its implications for reproductive health including the provision of modern contraception ........................................................................... 6
Provision of reproductive health care including family planning ...................................... 7
  The Family Planning Context ............................................................................................ 7
  Health service reform and its impact on issues related to access to modern contraceptives .... 9
  Health services and provision of pharmaceuticals including modern contraceptives: an overview of the evidence on the availability of modern contraceptives and contraceptive methods mix in the national market .................................................................................. 13
Fertility and use of contraception: analysis of access to, preferences and use of modern contraceptives by different population segments (segmentation by age, place of residence/location, education, wealth quintiles), and the determinants of consumption and unmet need .......... 17
  Knowledge of modern contraceptives ................................................................................ 17
  Use of modern contraceptives .......................................................................................... 19
  Unmet need for modern contraception ............................................................................. 21
  Induced abortion ................................................................................................................ 24
An overview of the evidence on the availability of modern contraceptives and contraceptive methods mix on the national market .................................................................................. 25
  Source of modern contraceptive methods ......................................................................... 25
Key Concepts – ability and willingness to pay and contracepting couple income ............ 29
  Deriving average income by population segments and sampling of pharmacies for collecting costs of contraceptives .......................................................... 30
Cost of modern contraceptives at pharmacies; prices charged for contraceptives in the commercial sector ................................................................. 31
Preparing ability to pay estimates for modern contraceptive in the country .................. 34
Segments of the population which are disadvantaged and high priority for the provision of modern contraceptives .................................................................................................................. 36
The case for subsidizing the provision of family planning in Moldova.......................... 36
Ability to pay analyses and follow-up of these analyses .............................................. 36
Specific findings: ability to pay analyses .................................................................... 36
Recommendations for meeting the contraceptive needs of different segments of the population and particularly the most vulnerable ones .......................................................... 37
Issues related to registration of contraceptives and the availability of contraceptives through the National Health Insurance Company ................................................................. 37
Provision of modern contraceptives for vulnerable populations .................................. 38
Forecasting contraceptive needs for the vulnerable population use and estimating costs ........ 41
Roadmap for implementation of the Total Market Approach ....................................... 46
Specific issues which need early attention .................................................................. 47
Activities which UNFPA could consider supporting the Government to strengthen family planning ................................................................................................................................................. 48
References ..................................................................................................................... 49
Appendix 1: Draft Agenda. In-country mission of Dr. Godfrey Walker, UNFPA International Expert to conduct the Market Segmentation Analysis for Modern Contraceptives in the Republic of Moldova ................................................................................................................................................. 53
Appendix 2: A series of pie charts showing the method mix for contraceptives used by women in 2012, by region of residence, urban and rural, woman’s age, number of living children, woman’s education level and wealth ........................................................................................................ 58

Figures

Figure 1: Map of the Republic of Moldova ........................................................................ v
Figure 2: Adolescent birth rates, 2012 by region, urban or rural, wealth and education level .... 9
Figure 3: Knowledge of specific contraceptive methods, 1997 and 2012 ............................ 18
Figure 4: Knowledge of specific modern contraceptives, 2005 and 2012 .......................... 18
Figure 5: Contraceptive use, women in union aged 15 to 49 years, 1997 to 2012 by contraceptive method .......................................................................................................................... 19
Figure 6: Use (and non-use) of contraception, currently married or in union women aged 15 to 49 years, 2012 ........................................................................................................ 20
Figure 7: Use of modern contraception by wealth quintiles, 2012 ..................................... 20
Figure 8: Use of contraception by location and education, 2012 ..................................... 21
Figure 9: Unmet need for modern contraception, currently married women.......................... 22
Figure 10: Unmet need for modern contraception, for spacing, for limiting and present use of
          traditional methods, married and women in union aged 15 to 49 years, 2012 .................. 22
Figure 11: Unmet need (married and in union women aged 15 to 49 years) for modern contraception
          by region, urban or rural, education and wealth, 2012........................................ 23
Figure 12: Unmet need for modern contraception, for spacing and limiting and use of traditional
          methods, women married or in union and all women 15 to 49 years, 2012.................... 23
Figure 13: Source used by people for modern contraceptives, 2005 .................................... 25
Figure 14: Source of modern contraception, 2005 ............................................................... 26
Figure 15: Contraceptives in one commercial pharmacy in a Primary Health facility ............... 27
Figure 16: The limited quantities of modern contraceptives (male condoms and IUDs) available at
          one health centre visited during this consultancy. These had been recently purchased locally,
          using available funds.................................................................................................. 28
Figure 17: Modern contraceptives bought locally by one Health Center in early 2017 from
          discretionary available budget. This included Depo-Provera® bought through the local office of
          Gideon Richter........................................................................................................... 28
Figure 18: Examples of condoms available in one Youth Friendly Health centre ..................... 29
Figure 19: Percentage distribution of income by quintile, Moldova 2015 ............................... 30
Figure 20: Estimated per capita income in Euros by population quintiles, 2015 ....................... 31
Figure 21: A selection of some male condoms on sale in a commercial pharmacy...................... 32
Figure 22: A selection of some oral hormonal contraceptives on sale in a commercial pharmacy..... 32

Tables

Table 1: Contraceptives included in National Essential Drug List ............................................ 14
Table 2: Contraceptives provided by UNFPA 2011 and 20012 .................................................. 27
Table 3: Male condoms procured 2012 to 2016 by UNFPA for Global Fund to Fight AIDS, TB and
          Malaria ....................................................................................................................... 27
Table 4: Prices of contraceptives in sampled pharmacies, May 2017 ........................................ 32
Table 5: Cost of contraceptives (using median price) as a percentage of annual income for couples 34
Table 6: Indicative international prices for procuring a range of modern contraceptives .......... 42
Table 7: Vulnerable priority segments of the population for provision of free family planning,
          projections for 2018 including indicative costs......................................................... 43
Acronyms

AMMD  Agency of Medicines and Medical Devices
ATP   Ability to pay
CCPPH Center for Centralized Public Procurements in Health
CDC   American Centers for Disease Control and Prevention
CoC   Combined hormonal oral contraceptive pill
CIS   Commonwealth of Independent States
CYP   Couple year of protection
DHS   Demographic and Health Survey
EDL   National essential drug list
FGP   Family Group Practitioners
FDC   Family Doctors Centre
FDO   Family Doctor Office
FP    Family Planning
GDP   Gross Domestic Product
GFATM Global Fund to Fight AIDS, Tuberculosis and Malaria
GNI   Gross National Income
HF    Health Facilities
HC    Health Centre
HO    Health Office
HIV   Human Immunodeficiency Virus
IUD   Intrauterine Device
LMIS  Logistics Management Information System
MHI   Mandatory health insurance
NHIC  National Health Insurance Company
MICS  Multiple indicator cluster survey
MLSPF Ministry of Labor, Social Protection and Family
MoH   Ministry of Health
MPA   Medroxyprogesterone acetate
NGO   Non-government Organization
NPSRHR National Program on Sexual and Reproductive Health and Rights
NRHS  National Reproductive Health Strategy
OOP   Out-of-Pocket Payment
PHC   Primary health care
PHCF  Primary Health Care Facility
RH    Reproductive Health
RH/FP Reproductive health including family planning
RHCS  Reproductive Health Commodity Security
SRH   Sexual and reproductive health
TFR   Total fertility rate
TMA   Total market approach
UNFPA United Nations Population Fund
WB    World Bank
WHO   World Health Organization
WRA   Women of Reproductive Age
WTP   Willingness to pay
YFHC  Youth Friendly Health Centre
Figure 1: Map of the Republic of Moldova
Acknowledgements

I would like to thank the many staff members of the Ministry of Health and other Government Departments and district health units in Chisinau and elsewhere in Moldova and several NGOs for providing time and information on issues related to contraceptive provision, distribution and use.

Many thanks to Rita Columbia, UNFPA Representative and all the staff of the UNFPA Country Office, including all the technical and administrative staff, who provided great support. I would like to give special thanks to Eugenia Berzan without whose tireless organisation and support I would not have been able to complete this mission.

In addition I owe a particular debt of gratitude and many thanks to Cristina Pascari who not only provided invaluable interpreting and translating help to me but also helped with undertaking the interviews in pharmacies and recording the information. Without her help I would not have been able to undertake this consultancy.
Executive Summary

Introduction

There is a clear case for improving access to modern contraceptives to all segments of the population in Moldova. Use of contraceptives has declined over the past 20 years from just over a half of married women to 42 percent. Unmet need for modern contraception has increased over this time and is high at 27 percent and even higher at 35 percent when all women of reproductive age are considered\(^1\). The figures of 27 percent and 35 percent unmet need represent estimations applying the definition used by the American Centers for Disease Control and Prevention (CDC) in Reproductive Health Surveys (as explained on the pages 18-20 of the present report) and are based on data from the 2012 Multiple Indicator Cluster Survey (MICS) together with figures provided by the Demographic Research Center.

The prevention of unintended pregnancies should be a priority in modern societies and enabling people to choose if and when they become pregnant, and how many children they have, is a basic right. Women empowerment, employment and integration are crucial elements for the wellbeing of women and of society as a whole, particularly in the current economic climate. It is therefore crucial that decision makers and competent authorities include modern contraceptive choice as a key component of integrated policies in the area of sexual and reproductive health.

There are important cost implications to providing contraceptive services to the increasing number of women needing modern contraceptives and to offering comprehensive, high-quality services to all users. At the same time, money spent on contraceptive services to help women avoid unintended pregnancies, has large health, social and economic benefits for women, families and society, and results in net savings to the health care system.

This market segmentation analysis for modern contraceptives in Moldova has shown that the market is divided into several segments. Most women of reproductive age do not have the ‘ability to pay’ for contraceptives. While the richest twenty percent of people of reproductive age is able to afford most types of contraceptives, the poorest forty percent segment only have the ability to purchase the cheapest IUDs and the middle segments - a very limited range of contraceptives.

In order to meet the various requirements of these different segments, a total market approach to modern contraceptives is required. The commercial sector should concentrate on marketing contraceptives for the most affluent segment of the population and the National Health Insurance Company should consider including a number of modern contraceptives on the list for medicines reimbursement. The poorest forty percent vulnerable segment of the population should have a limited range of contraceptives provided ‘free’ by the Ministry of Health, as part of a national programme.

A total market approach to the provision of modern contraceptives requires co-ordinated actions on the part of the public sector (principally the Ministry of Health and as part of that, the Medicines and Medical Devices Department; and also the Ministry of Labor, Social Protection and

Family), parastatal organisations (specifically the National Health Insurance Company), non-governmental organisations (including Bayer Pharmaceuticals, JV “RihPanGalFarma” Ltd. and the Joint Stock Company “MoldFarm”), pharmaceutical wholesalers (e.g. Sanfarm-Prim S.A.), commercial pharmacies (such as Felicia, Hippocrates, Farmacia Familiei and Odeon). And importantly medical and pharmacy undergraduate, postgraduate and continuing education establishments (particularly the Obstetrics and Gynaecology Departments, the Family Medicine Department, the Center for Simulation in Medical Training of the State Medical and Pharmaceutical University “Nicolae Testemitanu”) have a crucial role in achieving improved family planning care.

The Government (Ministry of Health) should as a matter of urgency establish a statutory technical group to develop a plan for the phased transition of the country to a total market approach, for the provision of modern contraceptives.

Recommendations on specific issues concerned with provision of modern contraceptives

After an assessment of the situation related to the availability of contraceptives and specifically the segmentation of the market in the country the following recommendations are made:

- Steps should be taken to explore how the two long-term contraceptives (medroxyprogesterone acetate injection and either the single-rod etonogestrel implant or the two-rod levonorgestrel implant) can be registered in the country and a commercial pharmaceutical company encouraged to import and market them. They should of course be made available through the Ministry of Health’s National Program on Sexual and Reproductive Health and Rights 2018-2022. It will be necessary to support training programmes for family doctors and gynaecologists in insertion and removal of hormonal implants.

- Representation should be made to the National Health Insurance Company for consideration to be given to placing a limited number of modern contraceptives on the list eligible for reimbursement e.g. Microgynon® - Bayer (30 mcg Ethinylestradiol and 150 Levonorgestrel) and Regulon® – Gideon Richter (Ethinylestradiol 0.03 mg, Desogestrel 0.15 mg), and possibly an emergency contraceptive (Levonorgestrel 1.5 mg) and a copper T IUD. When Medroxyprogesterone acetate and hormonal Implants are registered in the country, than these should also be included on the NHIC’s list of reimbursable pharmaceuticals. The inclusion of modern contraceptives in the NHIC’s list of reimbursable drugs would ease access of the middle segments of the population to contraceptives.

- Discussion should be had with representatives of pharmaceutical companies, importers and wholesalers of contraceptives and commercial pharmacies to market and promote cheaper combined hormonal contraceptives. This would help more affluent segments of the population to afford to purchase if they wish modern contraceptives.

- Continuing education initiatives, involving family doctors and gynaecologists, should be strengthened and based on objective evidence regarding different types of hormonal combinations and the absence of any discernible clinically significant difference between them.
• The draft NPSRHR 2018-2022 is a significant and far sighted development for which the Government deserves praise. It includes an Action Plan, a Monitoring and Evaluation Framework and a Costed Budget and the Ministry of Health needs to follow through with its implementation after approval. This should include acquiring expertise in estimation, procurement, distribution and monitoring of implementation. The establishment of a contraceptive logistics management information system is crucial for the effectiveness of the Program. The draft National Programme on Sexual and Reproductive Health includes an estimated Budget with a separate budget line for the procurement of modern contraceptives for vulnerable groups - equivalent to €300,000 per year. When approved by the Government - the respective amount will be available from the State Budget for the procurement of modern contraceptives in the period 2018-2022. According to the estimations reflected in Table 7 of this report – the €300,000 per year will not cover the needs of all the people in the seven categories of vulnerable groups, but in the initial stage it is worth to start with at least €300,000 per year allocated for procurement of modern contraceptives for vulnerable groups. When the contraceptive logistic management information system is established and well-functioning, then efforts to increase the budget allocation for the procurement of modern contraceptives for vulnerable groups from State Budget can be attempted.

• An information, education and communication campaign will be necessary to explain the objectives of the National Program on Sexual and Reproductive Health and Rights 2018-2022 and who (the vulnerable groups) is entitled to free contraceptives, and where they are available. This should include pamphlets and posters, to be displayed at appropriate MoH facilities.

• At a later stage, consideration might be given to establishing a social marketing programme for condoms and even of an oral contraceptive pill. For this to happen initially it would be useful to arrange a visit to the social marketing programme in Romania2.

• Monitoring implementation of the total market approach, will be important to assess if it is meeting its objectives. This could include periodic surveys of who is receiving contraceptives, from where and whether they are covered by the NHIC reimbursement scheme, or free contraceptives under the NPSRHR, or a purchasing them. The last Multiple Indicator Cluster Survey was carried out in 2012 and apparently a decision has not yet been taken on when, or if a further MICS will be undertaken, but there is a suggestion that it might be replaced by a mini-MICS. It is not clear what this might cover, but it is important if one is carried out, that it should include questions on contraceptive use, unmet need and supply and source of contraception.

Activities which UNFPA could consider, supporting the Government to strengthen family planning

It is suggested that UNFPA might consider providing assistance in: the development of standard care protocols (based on WHO’s Eligibility criteria for Contraceptive Use3) and one sheet algorithms for family doctors for different contraceptives in Romanian and Russian; training in estimation of contraceptive needs; training on establishing and running a contraceptive LMIS; continuing education in modern contraceptive technology; training on IUD insertion and use of Implants; development, printing and distribution of information


Market Segmentation Analysis for Modern Contraceptives in the Republic of Moldova

Terms of Reference for the Consultancy

This consultancy does not go into an extensive review of issues related to the recent history of reproductive health concerns in the Republic of Moldova, as this has been presented on several recent occasions elsewhere. However, key issues which have a bearing on the availability and use of modern contraceptives, are reviewed.

This report is concerned with assessing the market segmentation for modern contraceptives in the country. It aims to:

1. provide an overview of the evidence on the availability of modern contraceptives and contraceptive methods mix on the national market;
2. give an analysis of access to, preferences and use of modern contraceptives by different population segments (segmentation by age, place of residence/location, education, wealth/income quintiles), as well as to underline the determinants of consumption, and of the unmet need;
3. provide an analysis of the ability and willingness of different segments of population to pay for modern contraceptives in the commercial sector;
4. recommend interventions for meeting the needs of different segments of the population for modern contraceptives, particularly of the most vulnerable groups, as well as other disadvantaged segments of population;
5. develop a roadmap for implementation of the Total Market Approach, targeting all key players (public sector, social marketing, and commercial sector), with the aim to ensure a continuous supply of the spectrum of modern family planning (FP) commodities in the Republic of Moldova, meeting the need of all segments of population and particularly the most vulnerable groups;
6. define anticipated challenges and possible responses during the shifting to and implementation of the Total Market Approach.

---

Methods

The assessment has used a variety of methods in order to obtain a realistic view of the situation regarding the segmentation of the market for modern contraceptives in the country.

The methods used consisted of several surveys and analyses of existing information. In summary, information was compiled and analysed concerned with:

- Data on the availability of different contraceptives were reviewed.
- Existing information was sought on client and provider perspectives, related to the need for, and access to modern contraceptives.
- Information available from surveys was reviewed: on the use of a range of contraceptives (oral combined hormonal, IUDs, male condoms, and vaginal sprays and diaphragms), by different population segments (levels of wealth; location – rural/urban and regions; and education levels).
- Surveys were undertaken to obtain information on the costs charged for modern contraceptives. This was obtained from surveys of pharmacies and other outlets selling contraceptives.
- Analyses were performed of and estimates of the ‘ability to pay’ and the ‘willingness to pay’ of different income quintiles (segments) of the population.

A number of meetings were held with a range of key stakeholders in the regions, cities and districts (rayons), and visits were made to various health care facilities. Most importantly, to obtain data on the availability and costs of modern contraceptives in pharmacies, visits were made to over 20 pharmacies in different parts of the country. Interviews were made with pharmacists and the costs charged for a range contraceptives were recorded in order that variation in costs and ‘ability to pay’ could be carried out (see Appendix 1 for the schedule of visits).

Background

Introduction - Country Context

Moldova (Figure 1) is a former Soviet Republic and has been a fully independent nation since March 2, 1992, when Moldova also gained membership of the United Nations. The nation had declared its independence from the Soviet Union on August 27, 1991, and was a co-founder of the post-Soviet Commonwealth of Independent States.

While this report does not go into an extensive review of issues related to the recent history of reproductive health concerns in the Republic of Moldova, it does summarise relevant issues. The present economic situation, organisation and structure of health care in the country - affects the provision of reproductive health services, including those for family planning, and these relevant matters are briefly presented.
Poverty and its implications for reproductive health, including the provision of modern contraception

Moldova is classified by the World Bank as a lower middle income country with a per capita gross national income (GNI) in 2014 equivalent to US $2,2405 and ranks 107 on the Human Development scale, with an overall Human Development Index of 0.699 6. This low level of income in comparison to most other European countries means, that the ability to provide or purchase many commodities, including modern contraception, is severely constrained. In addition, while the proportion of the population living in poverty have fallen from a high of 30.2 percent of the population in 2006 to 11.4 percent in 2014 (latest figure)7,8 this means that over one in 10 families continue to be below the nationally defined poverty level.

Although Moldova has made considerable economic gains over the past decade, sustaining growth continues to be a challenge, as the gross domestic product (GDP) gains are led by remittances and export growth is dependent on volatile external markets. Remittances are estimated to account for almost 38 percent of Moldova’s GDP and there are high levels of income disparity. Per capita gross national income was estimated in 2015 (the most recent year for which information is available) at US $ 2,240 having fallen for the first time since 2001 from a high of US $ 2,560 in 20149. Over the 10 years from 2003 to 2013 the percentage of national income, held by the highest 10 percent, has fallen slightly from 27.3 percent in 2004 to 23.3 in 2013, but inequality in income continues to be substantial. There are specific issues related to corruption and Transparency International’s Corruption Perception Index 2016 ranks Moldova 123 on the list of a total 176 countries10.

Public expenditures on health services are relatively low at 5.3 percent of the GDP (2011-2015) and out-of-pocket payments (OOPs) remain very high, compared to European Union countries - at 38.4 percent (2011-2015) of total health expenditure11. A study carried out in 2012, found that OOPs were at 45 percent of total health expenditures, with more than two-thirds of outpatients having to buy prescribed medicines at a pharmacy12. In addition, a considerable proportion of patients reported making informal payments for care. Though many patients consider these payments to be gifts, around one-third had no choice but to make payments and thought this, a reflection of the limited list of reimbursable medicines, a desire to receive better treatment, and fear or extortion.

A study13 published in 2011, using data from the 2005 demographic health survey (DHS) examined the relationship between traditional contraceptive use and poverty and isolation, and found that economic disadvantage increases the probability of use of traditional methods, but the overall effect is small. The authors found that although higher family planning media

---

exposure decreased reliance on traditional methods among younger women, it had only a marginal effect in increasing modern method use among older women. Family planning programmes designed to encourage women to switch from traditional to modern methods have some success, although the effect is considerably reduced in regions outside Chisinau. The study concluded that family planning efforts, directed towards the poorest may have limited impact, but interventions targeted at older women could reduce the burden of unwanted pregnancies and abortions, and addressing differentials in accessing modern methods, could improve modern contraceptive uptake in rural areas.

Provision of reproductive health care including family planning

Reproductive Health (RH) has been a long-term priority in the Republic of Moldova and reform of health services since independence and particularly from 1994, have progressively led to the establishment of a national network of RH and family planning services. In 1999 a national programme for family planning and RH was endorsed by the Government. This set out a number of measures aiming to promote responsible sexual behaviours, avoid unplanned, or high-risk pregnancies and prevent sexually transmitted infections (STIs).

The Family Planning Context

A basic reproductive right is for all couples and individuals to decide freely and responsibly the number, spacing and timing of their children, to have the information and the means to do so, and the right to attain the highest standard of sexual and reproductive health. This implies access to modern contraception.

Moldova has achieved its MDG goal regarding poverty reduction, but access to universal education and reproductive health were not achieved. The Sustainable Development Goals (SDGs) came into effect in January 2016 and replaced the Millennium Development Goals. They comprise 17 goals designed to focus global development through 2030. Unlike the Millennium Development Goals, which preceded them, family planning is not explicitly stated in any of the SDGs. However it has been agreed, that reproductive health, including family planning is implicitly included under three goals - Goal 3 Ensure healthy lives and promote well-being for all at all ages, Goal 4 Ensure inclusive and quality education for all and promote lifelong learning and Goal 5 Achieve gender equality and empower all women and girls. Sustainable Development Goals 3 and 5 pledge universal access to sexual and reproductive health services and reproductive rights, and to integrate reproductive health into national policies. More broadly, other goals also commit to advancing gender equality, empowerment of women and girls, and improving child, adolescent and maternal health.

As mentioned earlier this market segmentation study does not intend to review all issues related to the provision of family planning services in the country, as these have been summarised elsewhere recently. However, some basic items concerned with the context in Moldova, are relevant.

---

The Republic of Moldova is one of the most densely populated European countries. The population structure of Moldova is rapidly changing with negative population growth, decrease in the proportion of adolescents, and increase in the proportion of the elderly. Emigration, mainly for work, is very common in Moldova and has a major impact on the demography and economy. Moldova is a source, and to a lesser extent, a transit and destination country - for human trafficking, both for sex and labour.17

- The 2014 national census enumerated the population at 2,804,80118 divided between three ‘regions’ north, centre and south, 32 districts, three municipalities and two autonomous territorial units.
- Over a half of the population are rural (57 percent) and the remaining 43 percent are urban. This figure is almost a quarter less than that estimated from earlier population projections.
- Fertility is below replacement with a total fertility rate (TFR19) of 1.24 (2016)20, 21 and this has steadily declined since 2006 when it was 1.8522, 23.
- It is estimated that almost a fifth (18 percent) of the population are aged 15 to 24 years, 10 percent 15 to 19 years and 8 percent 20 to 24 years.24
- In 2012 the adolescent birth rate was 35 per 1,000 girls 15 to 19 year olds (Figure 2). Adolescent birth rates25 are considerably higher among those living in rural areas and the less affluent, and are the lowest for adolescents living in Chisinau, and the richest 40 percent of people.

The situation regarding the sexual behaviour of young people has implications for the future population of the country and adolescent birth rates in Moldova are relatively high in comparison to other European countries. This probably reflects difficulties young people experience in accessing modern contraception.

A study26 carried out in 2014 on health behaviour among school aged children found that almost a fifth (18.3 percent) of 15-year olds and 38.8 percent of 17-year olds reported having had sexual intercourse. Among boys this was higher than among girls - 6.2 percent of those who had had sexual intercourse reported their first experience at age 11 or earlier, 8.1 percent at 12 to 13, 12.6 percent at 14, 28 percent at the 15, and 44.9 percent at the age of 16.

---

18 See NBS website http://www.statistica.md/pageview.php?f=ro&idc=479
19 The TFR of a population is the average number of children that would be born to a woman over her lifetime if she were to experience the current age-specific fertility rates through her lifetime.
20 See: http://eeca.unfpa.org/news/improving-demographic-policies-moldova-international-expertise but the 2012 MICS for the three years preceding 2012 found a rate of 2.2 births per woman.
24 See http://www.statistica.md/category.php?id=103
One third of sexually active adolescents reported using “coitus interruptus” during their last sexual intercourse, the 17-year olds indicating it 10 percent more often than 15-year olds, and boys seven percent more frequently than girls. It is a matter of concern that about one third of 15-year old boys and more than half of 17 year old boys have never used contraception in their last sexual intercourse, this being lower among girls.

Health service reform and its impact on issues related to access to modern contraceptives

Reform of the reproductive health (RH) system began shortly after independence and the modern concept of specialized RH services was realized by Ordinance No. 89/1994. This aimed to set up a national network of RH and family planning services. A national programme for family planning and RH was endorsed by Government Decision No. 527/1999 and has been designed to improve services at three levels of care, by integrating family planning (FP) and RH services within Primary Health Care (PHC), setting up structures at district/municipal level based on specific regulations, and providing patient referral mechanisms appropriate to their health care needs. PHC in the districts includes autonomous Health Centres, as well as units under them - Family Doctor’s Offices and Health Offices. In Chisinau, the PHC structure is comprised of comprehensive Territorial Medical Associations (TMAs) which each includes a few Centres of Family Doctors and one Consulting Diagnostic Center (staffed with medical specialists providing specialized ambulatory care). Besides TMAs, in Chisinau municipality there are - autonomous Health Centres.


---

and under them - Family Doctor’s Offices and Health Offices. In Balti Municipality – there is one Center of Family Doctors and responsible to it Health Centers and Family Doctor’s Offices.

PHC facilities in the Republic of Moldova are managed by the municipal/district authorities and are contracted by the National Health Insurance Company.

PHC services are funded by the Mandatory Health Insurance Fund on the per capita principle. Additionally, a performance-based incentive scheme in primary health care was introduced with aim to improve the performance (15% of the total PHC facilities Budget is provided by the NHIC to the respective institutions based on the level of achievement of a number of performance indicators). The package of medical services provided in PHC is stipulated in the ‘Unique Programme of Mandatory Health Insurance’.

RH cabinets are currently part of PHC facilities, located at the district/rayon level, as well as the municipal level. Government regulations state that all people, irrespective of health insurance status, have access to PHC services, but only those with insurance can obtain drugs compensated by the National Health Insurance Company (NHIC). Vulnerable groups should have access to free contraception, provided through centralized public procurements using PHC institutions funds, but until recently, definition of which vulnerable groups can access free contraception have been not very clear.

The National Reproductive Health Strategy (NHRS) 2005–2015 has just been completed and the National Public Health Strategy 2014-2020 was endorsed in line with the European policy “Health 2020”. This aims to improve access to high quality health services, and a healthier lifestyle remain national priorities. A draft document describing the National Programme on Sexual and Reproductive Health and Rights 2018-2022 has recently been developed and this includes an annual budget line for modern contraceptives procurement for vulnerable groups from State Budget. The draft policy document is due to be presented to the national Government for approval.

The Ministry of Health (MoH) has seen reproductive health, including family planning, as a priority concern, including improving access and coverage of services for the whole population. This has led to a series of orders covering these concerns: nr. 144 (2011) on Essential List of Drugs; nr 975 (2014) on the List of Contraceptives Recommended to be Procured at the Level of Primary Health Care; nr 600/320 (2015) on the mechanism for including medicines for compensation from the compulsory health insurance funds; nr 658 (2015) on Providing Contraceptives to Vulnerable Groups, procured at the level of primary health care from the compulsory health insurance funds; nr 786 (2015) on Amendments and Addenda to Annex to Order Nr 658 of 18 August 2015 on Providing Contraceptives; nr 228/139-A (2016) on Approving the Action Plan on providing contraceptives to vulnerable groups at the level of Primary Health Care.

We were informed that some family doctors are reluctant to prescribe hormonal contraception and this even applies in some cases to gynecologists. We were told that many women would prefer to have an IUD for contraception. However, although some of the family doctors have received training in the insertion of IUDs on inanimate models, they seldom, if ever, do this in

28 Managers of PHC facilities are allowed to use part of their budgets to purchase pharmaceuticals, including contraceptives, at prices determined by central tenders, but only some of them use this available resources for contraceptives procurement.
practice. Consequently for women to have an IUD inserted, they have to be referred and travel to a rayon level for a gynaecologist from Reproductive Health Cabinets to insert it. Occasionally gynaecologists based at the rayon level will visit PHC facilities from villages for IUD insertion, when needed.

When we asked pharmacists about the popularity of different brands of oral hormonal contraceptives, we were informed that often family doctors prescribed the more expensive brands and told women these were ‘best’, and consequently women, if they could afford them, would choose these brands.

Even though important steps have been taken in securing access to sexual and reproductive health (SRH) services, access is still influenced by the economic status of the population. Access to a number of SRH services depends on insurance status, because not all SRH services are included in the Unique Programme of Mandatory Health Insurance. The percentage of uninsured persons is about 15 percent (in 2014) and these people only benefit from the package of essential care, which does not include all SRH services. In addition, some people, although they are insured and should receive free services, cannot afford additional expenses associated with the use of the free services. This includes poor families, being unable to afford to purchase medicines, including contraceptives, or paying travel cost necessary to get to health services located in places other than where they live.

The Ministry of Health regulation (Order nr.695 of 13.10.2010) on Primary Health Care was meant to enable the provision of family planning services in primary health care institutions, in urban and rural areas - family doctors’ centers (FDCs), health centers (HCs), family doctor's offices (FDOs) - where there are family medicine practitioners (FMPs). Legislation is designed to ensure access to PHC services regardless of insurance status, theoretically allowing everyone to benefit from FP services. The Order no. 695 stipulates explicitly that FP is one of the obligations of the family doctor and family nurse (Section 11, Work organization, functions and rights of the family doctor, and Section 12, Work organization, functions, responsibilities and rights of family nurse). The MoH Order no.658 of 2015 lists categories of groups defined as ‘vulnerable’ including - sexually active adolescents, persons with low incomes, HIV positive persons, people addicted to alcohol, illegal and other drugs, those with psychiatric problems, victims of sexual abuse and women having had an abortion in the previous year - who should be able to access health services, including family planning services, without having payed insurance premiums.

However many financial, organizational, administrative and logistical reasons, why this has not been able to be achieved, were identified in a survey carried out in 2015. The most obvious reason is unavailability of contraceptives for free distribution. This is partly due to the limited funds available at the PHC level to purchase any pharmaceuticals, including contraceptives. Although managers of PHC level services are allowed to purchase contraceptives at prices agreed by central tenders, few do so; and since the ending of UNFPA donation of contraceptives, many PHC units do not have any modern contraceptives available. Most family doctors interviewed in

---

the 2015 survey, recommended that the MoH assumed responsibility for procuring and distributing contraceptives to PHC units.

To an extent, one vulnerable group - adolescents and young people, have benefited from the establishment of a network of Youth Friendly Health Centres located in Chisinau, Balti and at the districts level, where they can benefit from an array of services tailored to their specific needs, including free condoms; however only a limited number of them have easy access to free contraceptives.

The quality of PHC services is monitored by various mechanisms, such as internal controls and inspections. Institutions such as the National Evaluation and Accreditation Council and the National Health Insurance Company conduct periodic evaluations of institutions, including aspects of service quality. In general, however, quality assurance is still very limited.

Reform of health financing in Moldova began in earnest in 2004 with the introduction of a mandatory health insurance (MHI) system. Since then, MHI has become a financing mechanism, which has helped to further consolidate the prioritisation of primary care in the system that has been based on a family medicine model since the 1990s. However improving equity in financing and access to care, by reducing out-of-pocket (OOP) payments, remains a major challenge and OOP spending on health is dominated by the cost of pharmaceuticals. Public medical facilities are autonomous self-financing non-profit making organisations that are directly contracted by the National Health Insurance Company (NHIC) for the provision of medical services under MHI.

Initially there were issues regarding the third of the population who were uninsured, which included those self-employed (particularly in agriculture), unemployed, younger age and low income people. Those self-employed in agriculture were over 27 times more likely to be uninsured, than those who were employed. Agricultural workers were responsible for purchasing their own cover and most of these gave cost as the main reason for not doing so. In 2010 a WHO study advised on options to extend population coverage under the mandatory health insurance scheme and these included: 1) changing the way in which subsidies for insurance are targeted; 2) changes to improve the design and management of the mandatory health insurance scheme; and 3) proposals to further extend the package of health services provided, as a universal guarantee for all Moldovan citizens, irrespective of their health insurance status. This WHO study analysed - who was excluded and who covered by the MHI.

---

41 Richardson E, Roberts B, Sava V, Menon R, McKee M. Health insurance coverage and health care access in Moldova. Health Policy and Planning 2012; 27:204–212.
WHO has supported and contributed to development of the health sector in Moldova in several ways. The approach has ranged from specific work on maternal health, perinatal care and structural aspects of service provision in primary care and hospitals, as well as medicines. Concern about universal health coverage and concentrating on access to services, financial protection and quality of care, provided an opportunity to launch the process of strengthening quality of care systems throughout the entire Moldovan health sector in 2014, supported by the “EU-WHO Universal Health Coverage Partnership: Supporting policy dialogue on national health policies, strategies and plans and universal coverage”43.

To improve equity in the system, amendments to the Law on Mandatory Health Insurance in 2009 and 2010 sought to expand access to services by making access to primary care universal, and to increase the financial protection of vulnerable households by extending automatic MHI cover to families registered as living below the poverty line, even if they are formally “self-employed”. However recent studies by the WHO European Region have emphasised continuing challenges where supply side constraints and quality gaps, as well as informal payments are common44. The implementation of MHI has had substantial achievements as recently noted45, but there remains an unfinished agenda of attaining universal health coverage particularly in constraining excessive costs of pharmaceuticals including modern contraceptives46. Efforts, to expand financial protection, need to focus on reducing household spending on medicines47 and to consider ways to reduce medicine prices, and promote rational use, strengthen administrative controls and increase incentives for quality health care provision.

Health services and provision of pharmaceuticals, including modern contraceptives: an overview of the evidence on the availability of modern contraceptives and contraceptive methods mix in the national market

Major changes to pharmaceutical pricing and procurement policies have been attempted over recent years to improve access to pharmaceuticals, by introducing reference pricing and to ensure pharmaceuticals are not more expensive in Moldova than in neighbouring countries. This has included centralising procurement of essential medicines for public health facilities, which was meant to optimise purchasing power, but also to ensure that the supply of medicines is sufficient.

The Medicines Agency was created by the government in 2005 (now called the Agency of Medicines and Medical Devices) under the Ministry of Health and financed from the state budget. The Agency is responsible for the authorization of medicines, quality control of medicines, regulation of pharmaceutical activity, monitoring and coordinating of medicines supply and pharmaceutical care at the national level, and for collecting data on the pharmaceutical sector. The Agency maintains a National Essential Drug List (EDL); however a study48 in 2014 found there

is no consistent procedure and criteria for development of the national EDL, as advocated by WHO. The EDL includes combined hormonal and progesterone only oral contraceptives, three types of injectable hormonal contraceptives, emergency contraception, IUDs, male condoms, female diaphragm and hormonal implants (see Table 1).

Table 1: Contraceptives included in National Essential Drug List

<table>
<thead>
<tr>
<th>18.3 Contraceptives</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>18.3.1 Contraceptives orale</td>
<td></td>
</tr>
<tr>
<td>Etinilestradiol + levonorgestrel</td>
<td>Comprimate 30 mcg +150 mcg</td>
</tr>
<tr>
<td>Etinilestradiol + noretisteron</td>
<td>Comprimate 35mcg + 1 mg.</td>
</tr>
<tr>
<td>Levonorgestrel</td>
<td>Comprimate: 30 mcg, 750 mcg (două în cutie); 1,5mg</td>
</tr>
<tr>
<td>18.3.2 Contraceptive hormonale injectabile</td>
<td></td>
</tr>
<tr>
<td>Estradiol cypionat + Medroxiprogesteron acetate</td>
<td>Soluție injectabilă: 5 mg+ 25 mg.</td>
</tr>
<tr>
<td>Medroxiprogesteron acetate</td>
<td>Injecție depou: 150mg/ml în fioșă de 1ml</td>
</tr>
<tr>
<td>Noretisteron enatat</td>
<td>Soluție uleiosa: 200mg/ml în ampulă de 1ml</td>
</tr>
<tr>
<td>18.3.3 Dispozitive intrauterine</td>
<td></td>
</tr>
<tr>
<td>Dispozitive cu conținut de cupru</td>
<td></td>
</tr>
<tr>
<td>18.3.4 Metode de bariera</td>
<td></td>
</tr>
<tr>
<td>Prezervative</td>
<td></td>
</tr>
<tr>
<td>Diafragme</td>
<td></td>
</tr>
<tr>
<td>18.3.5 Contraceptive implantabile</td>
<td></td>
</tr>
<tr>
<td>Levonorgestrel-eliberare implant</td>
<td>Sistem cu cedare intrauterină 52 mg (20mcg/24h); Două tije levonorgestrel implant, fiecare tija conținând* 75 mg de levonorgestrel (150mg în total)</td>
</tr>
</tbody>
</table>


Physical access to places where pharmaceuticals, including modern contraceptives are available, is dependent on the location and coverage of commercial pharmacies. There has been some progress in reducing the number of villages with primary health-care facilities, but without a pharmacy49. Yet, even when there are local pharmacies, challenges persist in ensuring the availability of essential medicines. A 2011 study showed that less than half of public and private community pharmacies had in stock the cheapest generic drug and less than half had the full list of EDL reference generic drugs50. Rural areas were particularly disadvantaged51.

The present study found this continues to be the situation, with pharmacies in urban areas being more likely to stock the cheaper brands of modern contraceptives.

There are three main ways in which pharmaceuticals can be procured, or made available in the Republic of Moldova: centralized tendering (currently with the support of the Center for Centralized Public Procurements in Health (CCPPH), hospital tendering and direct purchase by

pharmacies\textsuperscript{52}. The pharmaceutical market relies heavily on imported medicines (91 percent of total value) and, to a lesser extent, on local production (9 percent of total value). Public and private pharmacies, on the other hand, acquire medicines through direct negotiation with wholesalers and/or local manufacturers.

The 2011 study found the majority of drugs (this study did not include modern contraceptives) available in pharmacies were unaffordable for many people owing to high prices, incomplete coverage and limited benefits for drugs under the social health insurance scheme. This study made many recommendations on all aspects of medicines in the country.

The NHIC maintains a list of pharmaceuticals which are eligible for reimbursement at 50, 70 or 90 percent of their commercial cost charged in pharmacies. The list of reimbursed medicines, including the fixed percent to be reimbursed, is approved jointly by the Ministry of Health and the NHIC. However modern contraceptives are not included on the medicines reimbursement list. We were informed by the General Director of the National Health Insurance Company that a committee meets monthly in connection with the list and while it considers new items for inclusion it has never met to remove items. He said resources to cover reimbursable drugs is limited, with many requests to include additional drugs. However, the list of reimbursed medicines is gradually being extended each year, depending on the funds available in the MHI system.

The NHIC contracts with individual pharmacies for the supply of MoH approved pharmaceuticals, and the NHIC reimburses the pharmacy at the agreed percentage of the cost price for each prescription. The allocation for reimbursed medicines is quite modest and constitutes only 4.3 percent of the basic MHI fund.

The list of reimbursed drugs continues to be limited and there are weak protection mechanisms for the chronically ill and the elderly. To approach universal health coverage and the comprehensiveness of the basic benefit, package for drugs needs to be broadened and safety-nets introduced for vulnerable groups. Apparently Moldova has a clear and efficient system for procurement and supply management of pharmaceuticals\textsuperscript{53}. Medical institutions act as independent contracting authorities and procure and use a centralized system for tendering and making medicines available. Medicines are delivered from the stores of the importer, or commercial agents to the destination.

There are eight national programmes (but not yet one for modern contraceptives) where selection, forecasting, procurement and monitoring is centralized. These national programmes are organized centrally by the MoH and are for: tuberculosis (TB); HIV/AIDS for antiretrovirals; diabetes mellitus; rare diseases; organ transplant; blood safety; mental health drugs; and oncology. These programmes from 2017 receive support from the UNDP procurement project mechanism and most use the centralized ‘Sanfarm-Prim’ storage facility in Chisinau. These programmes use an electronic system of logistics for managing the supply and distribution of medicines and it is possible, this will in the near future take part in the E-procurement system of Government.

The Medicines and Medical Devices Agency is responsible for the authorization of pharmaceuticals, based on the examination of documentation presented for each pharmaceutical item and on selective quality control testing to register medicines. Registration takes 90 days from European Union countries, the USA and other countries with similar well established registration


\textsuperscript{53} Ionesii L. Procurement and Supply Management in Moldova. Powerpoint. No date.
procedures; for products from other countries registration takes about 120 days. The cost for registration are very modest. Medicines are classified as prescription-only medicines, or medicines available ‘over-the-counter’ without a prescription.

Most pharmacies are private, but a few are publicly owned, or of a mixed form. Private pharmaceutical outlets can only dispense pharmaceuticals, if they have a licence issued by the Chamber of Licensing. The prices for medicines and other pharmaceutical products are established according to legal provisions, including a maximum mark-up of up to 40 percent from the delivery price of the local producer, and up to 15 percent for enterprises that import and/or distribute wholesale imported and locally produced medicines, and a further retail mark up of up to 25 percent can go to the pharmacies and their branches. A value added tax of eight percent is also applied. The Ministry of Health approves producers’ prices on medicines included in the National EDL Catalogue, which is the average price of the lowest three prices for the same medicine in certain reference countries. For products from CIS Member States, the information regarding the comparison between the proposed price and the authorized producer’s price is presented for two reference countries. For producers’ prices from other countries, the comparison between the proposed price and the authorized producer’s price is compared with at least three reference countries, taken from Romania, Greece, Bulgaria, Serbia, Croatia, Czech Republic, Slovakia, Lithuania and Hungary.

The following 20 oral hormonal contraceptives are registered\(^{54}\) in the country: Artizia\(^{®}\), Belara\(^{®}\), Dimia\(^{®}\), Dvella\(^{®}\), Escapelle\(^{®}\), Lactinette\(^{®}\), Lindynette\(^{®}\) 30, Lindynette\(^{®}\) 20, Logest\(^{®}\), Microgynon\(^{®}\), Midiana\(^{®}\), Novynette\(^{®}\), Postinor\(^{®}\), Qlaira\(^{®}\), Regulon\(^{®}\), Rigevidon\(^{®}\), Tri-regol\(^{®}\), Yasmin\(^{®}\), Yaz\(^{®}\) and Zoely\(^{®}\).

In 2015 the Ministry of Health with the Center for Reproductive Health Training (CIDSR) with the assistance of United Nations Population Fund (UNFPA) - carried out a wide ranging assessment of the barriers and factors which limit the provision of and access to family planning services in primary health care in the country\(^{55}\). This included interviews with family doctors and other providers and a review of education curricula on family planning for service providers.

This assessment report identified many barriers to the provision of family planning and in particular modern contraceptives to all groups in the population, and specifically those who are socially vulnerable. To improve the situation, recommendations were provided, included: developing efficient mechanisms for the supply of contraceptives; increasing the role of the family doctor and their team in providing FP services; streaming their cooperation with other institutions and actors in reproductive health; development of a system for the accreditation of facilities offering family planning services; delegation by the Ministry of Health to a single structure/republican institution the role to manage the system for the procurement and distribution of contraceptives. This would ensure centralized procurement, monitoring and evaluation of the provision of contraceptives and particularly those to persons of reproductive age in socially vulnerable groups, and monitoring stocks; development of criteria for defining socially vulnerable groups and mechanisms for identification and registration of them and monitoring their use.

\(^{54}\) Information provided Medicines Agency May 2017

In line with the MoH order no. 658 of 2015, PHC service providers have suggested the vulnerable group eligible for free contraceptives should be the following categories: poor women, those addicted to alcohol/drugs, those with many children, sexually active teenagers, women who have had an abortion in the previous year, women with mental health disorders and those with children aged up to three years, and also those at obstetric and extra genital risks. The report recommended that a centralised system for procurement of contraceptives should be established and the existing logistics system for distributing contraceptives would allow health facilities to cover the needs of socially vulnerable groups in specific localities. Small value contracts for the purchase of contraceptives devolved to Primary Health Care facilities would cease.

Fertility and use of contraception: analysis of access to, preferences and use of modern contraceptives by different population segments (segmentation by age, place of residence/location, education, wealth quintiles), and the determinants of consumption and unmet need

Over the past 20 years, four population based surveys have been carried out and information collected on reproductive health, including family planning in the country. These have provided an insight into changing patterns of knowledge about, availability and use of contraceptives.

Knowledge of modern contraceptives

The level of awareness of different methods of contraception has increased slightly over the 20 years and overall is very high (see Figure 3, Figure 4). Not surprising, certain contraceptives such as, the female condom and emergency contraception were not known in 1997; but by 2012 over 60 percent knew of emergency contraception (see Figure 3, Figure 4). In 2012 there was virtually no difference in knowledge by residence (urban and rural), age, education, or wealth.

Very limited information is available on the extent to which people understand the precise nature, and how to use different types of modern contraception. There is also very little information on myths and misconceptions about modern contraceptives and particularly hormonal methods, but it is alleged that there is some reluctance by physicians to prescribe hormonal contraceptives, largely due to historical reasons with concerns about the side effects of high levels of particularly oestrogens used during Soviet times, while now only low dose products are available.

Figure 3: Knowledge of specific contraceptive methods, 1997 and 2012


Figure 4: Knowledge of specific modern contraceptives, 2005 and 2012

The Demographic and Health survey (DHS) carried out in 2005 provides the most recent, more detailed information on knowledge of modern contraceptives, including side effects. This DHS found that 45 percent of users of modern contraceptives were informed about the side effects, or health problems of the method they were provided with. Forty four percent were informed of what to do if they experienced side effects, but only 37 percent of women who were using a modern method said they were told about other methods that they could use.

Almost half of women said they have seen a family planning message on the television, while about one-third said they heard about family planning on the radio, or read about it in a newspaper, or magazine in the previous few months. Only about one in four women said they heard about family planning in a pamphlet/brochure, or at a community event. Men were far less likely than women to say they have been exposed to family planning information. Less than one-third of men heard about family planning on the television, while less than one-quarter were exposed to information through the radio, newspaper or magazines, and only about 10 percent through pamphlets/brochures, or community events.

It is likely that these largely positive attitudes to modern contraception and reasonable levels of knowledge continue to apply at the present time.

Use of modern contraceptives

The level of use of modern contraceptives among married or in union women has declined over the past twenty years from just over a half (50.1 percent) in 1997 to 41.7 percent in 2012 (Figure 5).

Figure 5: Contraceptive use, women in union aged 15 to 49 years, 1997 to 2012 by contraceptive method

There has been a marked fall in the use of IUD (from a prevalence of 38.4 percent in 1997 to 19.8 percent in 2012), and an increase particularly in use of condoms and pills. However, overall the most frequently used modern contraceptive continues to be the IUD (Figure 6).

Figure 7: Use of modern contraception by wealth quintiles, 2012
Use of modern contraceptives is highest among the wealthiest 40 percent of the population at 45 percent compared to the poorest 20 percent whose use is 34 percent (Figure 7). Those living in urban areas and particularly Chisinau have higher use of modern contraceptives compared to rural people (Figure 8). Similarly, those with higher levels of education, are more likely to use contraception.

Figure 8: Use of contraception by location and education, 2012

There are marked differences in the method mix within these categories (see appendix 2). For instance: IUD use is more common in the south region (at 23.1 percent), compared to the other regions and particularly Chisinau (at 13.1 percent); condom use is more frequent in urban areas (at 17.6 percent), compared to those in rural areas (at 8.2 percent); older people are more likely to use IUDs and younger ones - condoms.

Unmet need for modern contraception

Unmet need (fecund women who are married or in union and are not using any method of contraception, but who wish to postpone the next birth, or want to stop childbearing) is high. However if the definition used by the CDC in Reproductive Health Surveys57, which also includes those using traditional methods, and is considered to be more appropriate for countries including Moldova, then unmet need for modern contraception is very high at 27.2 percent of married couples in 2012 (see Figure 9 and Figure 10).

---

Figure 9: Unmet need for modern contraception, currently married women

![Figure 9](image-url)


Figure 10: Unmet need for modern contraception, for spacing, for limiting and present use of traditional methods, married and women in union aged 15 to 49 years, 2012

![Figure 10](image-url)


---

58 The definition of unmet need is the one used by the CDC reproductive health surveys, see Measure evaluation. 
https://www.measureevaluation.org/prh/rh_indicators/specific/fp/unmet-need-for-family-planning

Unmet need for family planning for the 1997 RHS is women 15 to 44 years, for the 2005 DHS and the 2012 MICS it is women 15 to 49 years.
Unmet need for modern contraception is highest among those living in rural areas, the north of the country, those with the lowest levels of education and significantly among the poorest 20 percent at 32.3 percent compared to 24.4 percent among the wealthiest (see Figure 11).

Figure 11: Unmet need (married and in union women aged 15 to 49 years) for modern contraception by region, urban or rural, education and wealth, 2012

Unmet need for modern contraception is considerably higher when all women aged 15 to 49 years (at over a third) are included as against restricting consideration only to women who are married or in union (at about a quarter) (see Figure 12). These increased percentages among all women are particularly higher for the poorest, those with the least education and women living in rural areas.

Figure 12: Unmet need for modern contraception, for spacing and limiting and use of traditional methods, women married or in union and all women 15 to 49 years, 2012


Induced abortion

Reliance on induced abortion was an important form of fertility control throughout the former Soviet Union, including the former Soviet Republic of Moldova. In the decade after Moldova’s independence in 1991, abortion rates began to decrease, as the practice of modern contraception became more widespread. However, as has been made clear earlier, prevalence of modern contraception over the past 15 or so years, has plateaued. Induced abortion continues to be an important form of fertility control.

Like other countries in Eastern and Central Europe, and the former Soviet Union, Moldova’s abortion laws are among the most liberal in the world. They allow women to obtain a voluntary abortion upon request up to the 12th week of pregnancy, and up to 21st week in case of socioeconomic and medical reasons. For various reasons, including limited access to modern contraception, abortion continues to be an important form of fertility control. The abortion rate in Moldova has declined sharply since independence from in 1989 a rate of 93.0 abortions per 1,000 women aged 15 to 44 years, which was among the highest reported rates in the Soviet Union. The reported rate fell to 50 in 1994, 38.8 in 1996, 30.8 in 1998, 17.6 in 2004, and 18.0 in 2010, and in 2015 the rate was 21.5 abortions per 1000 women aged 15-44 years. However probably figures for recent years are under reported because many are carried out privately and also by using Cytotec (Misoprostol) and Mt Pill (mifepristone), as medical abortion has become widely accepted and practised.

Data from the 2005 DHS found a lifetime total abortion rate for the three-year period prior to the survey (from mid-2002 to mid-2005) of 1.1 abortions per woman. The TAR was slightly higher in urban areas than rural areas (1.3 and 1.0, respectively). These rates are lower than for the neighbouring countries of Romania (2.2) and Ukraine (1.6).

The lowest TAR of 0.7 was seen for women in the poorest wealth quintile, while the highest TAR (1.4) was for women in the highest quintile, and also for women in Chisinau. Higher abortion rates among these wealthier women are probably due to the fact that because abortions are no longer covered by the state, women with adequate resources are more likely to have access to abortion and to be able to afford the procedure.

Advice on access to different types of induced abortion are available from the Reproductive Health Training Center of the Republic of Moldova (RHTC), a non-governmental organization, founded in 1998, the Center with the MoH maintains a monitoring system and the coverage of these statistics are considered to be high. Based on this system it is estimated that the annual abortion rate is 15 abortions per 1,000 women aged 15 to 49 years or 12,635 per year.

We were informed by Dr Rodica Comendant, the Director of the RHTC that of termination of pregnancies - about 15 percent were by medical means, 70 percent by aspiration and 15 percent by D&C. We were informed that an abortion carried out by aspiration costs about € 20 and one carried out by medical means € 30, and although we were told that misoprostol and mifepristone

59 See http://www.johnstonsarchive.net/policy/abortion/ab-moldova.html
is only available on prescription, we could have purchased them without a prescription in some pharmacies at a cost of about € 34. Induced abortion is not covered by the NHIC.

An overview of the evidence on the availability of modern contraceptives and contraceptive methods mix on the national market

Source of modern contraceptive methods

It is helpful to have an understanding of where people are obtaining their contraceptive supplies, in order to see the adequacy of access and coverage of modern contraceptives. The only representative information on the source from which people are obtaining their contraceptives is from the DHS of 2005. This shows that at that time in 2005, public (government) facilities provided contraceptives to more than two in three users (69 percent), while 28 percent of users obtained their contraceptives from commercial pharmacies and private medical sources, and three percent through other private sources such as shops (Figure 13).

Figure 13: Source used by people for modern contraceptives, 2005

The most common single source of contraceptives in Moldova was government hospitals, which supplied one-third of all users of modern methods. Family doctors and pharmacies, each supplied about one-quarter of users, while government family planning offices only supplied seven percent

---

of users. Private hospitals and clinics, and private doctors at that time accounted for only a very small share (two percent) of contraceptive provision.

Government sources, supplied almost all users of long-term methods, such as female sterilization (99 percent) and IUD (95 percent). However, the large majority of pill and condom users obtained their methods from private sources, especially pharmacies. Nevertheless at that time, one-third of pill users obtained their supplies from government sources (see Figure 14).

Figure 14: Source of modern contraception, 2005

It is not clear to what extent the source of contraceptives, which people use, has changed over the past 10 or so years, but given the change in the method mix of contraceptives used by people with less reliance on long acting methods over this time, and that UNFPA ceased to donate contraceptives in 2012, there must have been a considerable shift in people obtaining their contraceptives from the public to the private sector.

There is a dynamic commercial market in a range of modern contraceptives, which are available for purchase from pharmacies and other outlets; and many pharmacies have over 15 different brands of contraceptive pills on sale.

UNFPA has provided supplies of modern contraceptives (combined hormonal pills, copper IUDs, Depo-Provera® and condoms) since the mid 1990 until 2012 (see Table 2), when with the designation of Moldova, as a lower middle income country, this ceased65.

---

Table 2: Contraceptives provided by UNFPA 2011 and 2012

<table>
<thead>
<tr>
<th>Year purchased</th>
<th>Contraceptive</th>
<th>Quantities</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>IUDs copper T 380A</td>
<td>30,000 pieces</td>
</tr>
<tr>
<td></td>
<td>Depo-Provera® and syringes</td>
<td>4,000 sets</td>
</tr>
<tr>
<td></td>
<td>Microgynon® 30</td>
<td>149,760 cycles</td>
</tr>
<tr>
<td>2012</td>
<td>Condoms, male</td>
<td>2,016,000 pieces</td>
</tr>
<tr>
<td></td>
<td>Marvelon</td>
<td>149,580 cycles</td>
</tr>
<tr>
<td></td>
<td>Exiluton</td>
<td>39,936 cycles</td>
</tr>
</tbody>
</table>

Through the UNFPA Procurement Services – the Public Institution “Coordination, Implementation and Monitoring Unit of the Health System Projects” (UCIMP) which implements the Global Fund to Fight Aids, TB and Malaria grants, procured in 2012, Standard Male Condoms 53 mm (2,200,032 pieces) (Table 3).

Table 3: Male condoms procured from 2012 to 2016 by local implementing partners of Global Fund to Fight AIDS, TB and Malaria grants (NGO PAS Center; UCIMP), including via UNFPA Procurement Services.

<table>
<thead>
<tr>
<th>Year purchased</th>
<th>Contraceptive</th>
<th>Quantities</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>Condoms, male</td>
<td>2,200,032</td>
</tr>
<tr>
<td>2015</td>
<td>Condoms, male</td>
<td>1,280,160</td>
</tr>
<tr>
<td>2016</td>
<td>Condoms, male</td>
<td>1,883,232</td>
</tr>
</tbody>
</table>

On our visits to PHCFs and YFHCs we found very few contraceptives available at primary healthcare facilities and youth friendly health centres (YFHCs)66. Although, the commercial pharmacies in some Primary Healthcare facilities have a range of oral hormonal contraceptives and condoms (Figure 15).

Figure 15: Contraceptives in one commercial pharmacy in a Primary Healthcare facility

---

Towards the end of 2016 some PHCFs had very limited quantities of pills and condoms and virtually none had IUDs or injectable contraceptives. In some instances, the limited amounts of modern contraceptives available in PHCFs, are those remained from the final UNFPA donation provided in 2012.

Figure 16: The limited quantities of modern contraceptives (male condoms and IUDs) available at one health centre visited during this consultancy. These had been recently purchased locally, using available funds.

Some PHCFs managers purchase locally contraceptives using their discretionary funds allocated for purchase of pharmaceuticals and other supplies (Figure 17). Although, there are many demands on these limited funds available, and contraceptives are one of many pharmaceuticals and other supplies in short supply (Figure 16).

Figure 17: Modern contraceptives bought locally by one Health Center in early 2017 from discretionary available budget. This included Depo-Provera® bought through the local office of Gideon Richter.
A similar situation was found at one YFHC, see Figure 18.

Figure 18: Examples of condoms available in one Youth Friendly Health centre

Key Concepts – ability and willingness to pay and contraceptive couple income

The ability to pay (ATP) refers to how easy it is for consumers to find the money necessary to pay for, in this case, contraceptives. An ATP analysis assumes that the lower the relative cost of contraceptives, in relation to income, the greater the ability of users to pay for them, and there is good international evidence for this. The approach used to measure ATP involves deriving the average annual income of contraceptive couples by income quintile (five equal population subgroups), and comparing this to the cost of a couple year of protection (CYP) for different methods and brands, and from different sources.

An estimate frequently used to measure ATP, assumes that expenditure on contraceptives should be no more than one percent of per couple income. Couples who would have to exceed one percent of income on contraceptives, are considered to be unable, or less likely to pay. However the one percent estimate may be biased toward middle income populations with more disposable income, than toward poorer income groups.

There is a large amount of evidence from many countries that the use of modern contraceptives is very sensitive to price, with quite small increases in price, resulting in reductions in use of contraception. Using per capita income to estimate affordability - is not a perfect solution. Some contraceptive couples have access to either household, or spousal income and it is reasonable if you assume that contraceptives are purchased by one or the other, but not by both members of couples. Therefore, estimates of ATP often consider a lower income threshold, such as 0.5 percent, for the poorest 40 percent of the population.

Analysis of RH accounts in several countries by the World Bank suggest estimates of around 0.5 percent of couple income on contraceptives may be more realistic, given household expenditures on other (reproductive) health care services and commodities. To obtain an indication of ATP, contraceptive costs by method and brand, and by source are then compared to income quintiles, producing a cost to income ratio expressed as a percentage. This analysis provides an indication of what methods and brands are affordable to each income quintile.

In contrast to ATP, willingness to pay (WTP) reflects the value customers place on contraceptives. Consumers, of course, may make decisions to spend more than one percent of couple income, because of the value they place on the product. Interviews with pharmacists and physicians indicated that some women were willing to pay very high prices for the oral contraceptives (e.g. Yasmin® €8 for one cycle, Yaz® €10 for one cycle). While this evidence is only anecdotal, there is a marked distinction between the ability and willingness to pay. In the absence of an alternate for defining a benchmark, analyses in this report categorizes users as unable to pay, if the price exceeds 1.0 percent of annual couple income (2 x per capita income). This does not necessarily mean households are unwilling to pay, but are certainly less likely, given their income. Couples will be considered able to pay, if the price is below 1 to 1.5 percent of income.

Deriving average income by population segments and sampling of pharmacies for collecting costs of contraceptives

Estimating the ATP for contraceptives first requires data on the percentage of national income, by population segments or quintiles. Mean per capita income for each quintile was calculated using World Bank income data for 2015 and income distribution data from 2015 (Figure 19) the most recent year for which this data is available.  

The World Bank’s most recent estimate of the per capita gross national income (GNI) is for 2015 and came to an equivalent to US 2,240. This is based on an estimated population of 3.5 million which is the figure available when the World Bank’s estimate was made. However the results of the 2014 national census are now available and this enumerated the population at 2,804,801. This figure has been used and the GNI per capita adjusted to take account of the lower population figure from the 2014 national census (Figure 20).

Figure 19: Percentage distribution of income by quintile, Moldova 2015


---

70 A conversion rate of US$ 1 = €0.9144 was used; [http://www.xe.com/](http://www.xe.com/) accessed May 2017.


Cost of modern contraceptives at pharmacies; prices charged for contraceptives in the commercial sector

Over 20 private pharmacies selling contraceptives were visited to determine available brands, methods and price of contraceptives. The pharmacies represented convenience samples, however, in a sense, the sample was also purposive. An effort was made to obtain a diverse sample, including urban and rural pharmacies in all of the regions in the country, and various parts of Chisinau.

Table 4 presents data on median unit prices recorded from the pricing survey, by method and brand charged for condoms, pills, IUDs, emergency contraception, vaginal foams and other contraceptives sold in Moldova. For most specific brands there is some price variation between pharmacies in different parts of the country. This probably largely reflects competition and availability from a range of outlets.

In general, there was a wide range of contraceptives available, including many brands of and oral combined hormonal pills, several brands of emergency contraceptives, IUDs and contraceptive foams (Figure 21 and Figure 22). In a few pharmacies there were even hormonal vaginal rings and Mirena® the hormone-releasing IUD. Pharmacies reported the sales of condoms with prices ranging from € 8 cents to the most expensive at € 90 cents per piece, and from € 11 for one cycle of the most expensive oral contraceptive to € 2.5 for the cheapest CoC (Table 4).

When speaking with pharmacists, and asking which oral contraceptives are the most popular we were told that generally is Yaz®, Dimia® and Yasmin®. These are all the most expensive of the range of over 15 oral hormonal contraceptives on sale, and when asked, the pharmacists said that these were the brands that the family doctors and gynecologists often highly recommend to women. We also understand that Gideon Richter, Bayer and local pharmaceutical distributors have numbers of representatives (detail men) who regularly visit pharmacies and family doctors and gynecologists and give free ‘samples’ to them of the products they are marketing.

---

73 Pharmacies in central Chisinau, several areas of Chisinau Municipality, Cimislia District, Hincesti District, Ungheni District, Calarasi district, Causeni District Anenii-Noi District and Bulboaca Village, Costesti village from Ialoveni District were visited and cost figures for contraceptives obtained.
Figure 21: A selection of some male condoms on sale in a commercial pharmacy

Figure 22: A selection of some oral hormonal contraceptives on sale in a commercial pharmacy

Table 4: Prices\textsuperscript{74} of contraceptives in sampled pharmacies, May 2017

<table>
<thead>
<tr>
<th>Brand of contraceptive</th>
<th>Median price in € at pharmacies in sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lindynette® 20</td>
<td>3.1</td>
</tr>
<tr>
<td>Rigevidon®</td>
<td>4.4</td>
</tr>
<tr>
<td>Dimia®</td>
<td>7.0</td>
</tr>
<tr>
<td>Tri-regol®</td>
<td>7.1</td>
</tr>
<tr>
<td>Regulon®</td>
<td>4.1</td>
</tr>
<tr>
<td>Yaz®</td>
<td>10.0</td>
</tr>
<tr>
<td>Belara®</td>
<td>9.4</td>
</tr>
<tr>
<td>Qlaira®</td>
<td>10.8</td>
</tr>
<tr>
<td>Midiana®</td>
<td>4.7</td>
</tr>
</tbody>
</table>

\textsuperscript{74} A conversion rate of € 1 = MDL 20.44 was used; \url{http://www.xe.com/}, accessed May 2017,
<table>
<thead>
<tr>
<th>Contraceptive Type</th>
<th>Brand(s)</th>
<th>Price (in parentheses indicates insufficient numbers to obtain a reasonable indication of price.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Progestone only</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lactinette®</td>
<td>9.1</td>
</tr>
<tr>
<td>Emergency contraception</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Postinor®</td>
<td>6.6</td>
</tr>
<tr>
<td></td>
<td>Escapelle®</td>
<td>8.2</td>
</tr>
<tr>
<td>IUDs</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mirena®</td>
<td>130.2</td>
</tr>
<tr>
<td></td>
<td>Yunona® T cu</td>
<td>19.6</td>
</tr>
<tr>
<td></td>
<td>Yunona® Bio T</td>
<td>3.4</td>
</tr>
<tr>
<td></td>
<td>Yunona® bio multi</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Yunona® T super</td>
<td>6.3</td>
</tr>
<tr>
<td></td>
<td>IUD generic T Chinese</td>
<td>2.7</td>
</tr>
<tr>
<td>Condoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Durex®</td>
<td>0.9</td>
</tr>
<tr>
<td></td>
<td>Lex</td>
<td>0.3</td>
</tr>
<tr>
<td></td>
<td>Vizit</td>
<td>0.7</td>
</tr>
<tr>
<td></td>
<td>Dolphin</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>Playboy</td>
<td>0.9</td>
</tr>
<tr>
<td></td>
<td>One Touch</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>Wadex</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>You libido</td>
<td>0.3</td>
</tr>
<tr>
<td></td>
<td>Masculin</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>Romed</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td>Innotex</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>Sico</td>
<td>0.5</td>
</tr>
<tr>
<td>Vaginal ring</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nova ring</td>
<td>10.0</td>
</tr>
<tr>
<td>Vaginal tablets</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pharmatex, vaginal suppositories, pack of 10</td>
<td>5.0</td>
</tr>
</tbody>
</table>

* Insufficient numbers to obtain a reasonable indication of price.

The prices charged for contraceptives are high in comparison to income and the cost of living. Prices are slightly higher in rural and are less accessible, and particularly, less affordable.

---

Preparing ability to pay estimates for modern contraceptive in the country

The annual cost of contraceptive protection for each type and brand being sold in pharmacies, was determined by multiplying the median unit price (Table 4) by the standard couple-year of protection (CYP) factor for each method\textsuperscript{76}. Internationally agreed CYP factors used for the analysis, were 120 condoms per year, 15 cycles of pills, 4.6 years per IUD, 3.3 years for a five year LNG-IUS IUD, and 20 doses for emergency contraceptive pills.

The cost of a year’s protection from becoming pregnant, as a percentage of annual income, was determined by dividing the annual cost per CYP for each brand by contracepting couple income, for each income quintile segment of the population (see Figure 19 and Figure 20). As discussed earlier, household expenditures of amounts spent for contraceptives above 1.0 percent of annual contracepting couple income are usually considered excessive and generally unsustainable. Unusually contracepting couples may be willing to pay in excess of 1.5, 2.0, or even 3.0 percent of income; however, an assumption was made that 1.0 percent, for the situation in Moldova, is the ceiling where customers reach their maximum ATP. In Table 5 percentages of income exceeding 2.0 percent are shaded yellow, between 1.0 and 1.9 are shaded in red and below 1.0 percent in blue.

Table 5: Cost of contraceptives (using median price) as a percentage of annual income for couples

<p>| Contracepting Couple (i.e. Double the per capita figure) Gross National Income in Euros | | | | | | |
|---|---|---|---|---|---|
| Source: Commercial Pharmacies and drug stores | Euros | Q1 Poorest 2,338 | Q2 3,422 | Q3 4,418 | Q4 5,748 | Q5 Richest 9,672 | Mean 4,518 |</p>
<table>
<thead>
<tr>
<th>Method</th>
<th>Brand</th>
<th>Cost per CYP</th>
<th>Cost as a Percentage of Annual Income</th>
</tr>
</thead>
<tbody>
<tr>
<td>Condoms</td>
<td>Lex 36</td>
<td>1.5</td>
<td>1.1</td>
</tr>
<tr>
<td></td>
<td>Vizit 84</td>
<td>3.4</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td>Playboy 108</td>
<td>4.6</td>
<td>3.2</td>
</tr>
<tr>
<td></td>
<td>Dolphin 60</td>
<td>2.6</td>
<td>1.8</td>
</tr>
<tr>
<td></td>
<td>One Touch 60</td>
<td>2.6</td>
<td>1.8</td>
</tr>
<tr>
<td></td>
<td>Durex® 108</td>
<td>4.6</td>
<td>3.2</td>
</tr>
<tr>
<td></td>
<td>You libido 36</td>
<td>1.5</td>
<td>1.1</td>
</tr>
<tr>
<td></td>
<td>Masculin 60</td>
<td>2.6</td>
<td>1.8</td>
</tr>
<tr>
<td></td>
<td>Romed 12</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>Innotex 48</td>
<td>21</td>
<td>1.4</td>
</tr>
<tr>
<td></td>
<td>Sico 60</td>
<td>2.6</td>
<td>1.8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COCs</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Diane® 35</td>
<td>64.5</td>
<td>2.8</td>
<td>1.9</td>
<td>1.5</td>
<td>1.1</td>
</tr>
<tr>
<td>Tri-regol®</td>
<td>106.5</td>
<td>4.6</td>
<td>3.1</td>
<td>2.4</td>
<td>1.9</td>
</tr>
<tr>
<td>Yaz®</td>
<td>150</td>
<td>6.4</td>
<td>4.4</td>
<td>3.4</td>
<td>2.6</td>
</tr>
<tr>
<td>Yasmin®</td>
<td>115.5</td>
<td>4.9</td>
<td>3.4</td>
<td>2.6</td>
<td>2.0</td>
</tr>
<tr>
<td>Lindynette®</td>
<td>46.5</td>
<td>2.0</td>
<td>1.4</td>
<td>1.1</td>
<td>0.8</td>
</tr>
<tr>
<td>Microgynon®</td>
<td>37.5</td>
<td>1.6</td>
<td>1.1</td>
<td>0.8</td>
<td>0.7</td>
</tr>
<tr>
<td>Dimia®</td>
<td>105</td>
<td>4.5</td>
<td>3.1</td>
<td>2.4</td>
<td>1.8</td>
</tr>
<tr>
<td>Regulon®</td>
<td>61.5</td>
<td>2.6</td>
<td>1.8</td>
<td>1.4</td>
<td>1.1</td>
</tr>
<tr>
<td>Belara®</td>
<td>141</td>
<td>6.0</td>
<td>4.1</td>
<td>3.2</td>
<td>2.5</td>
</tr>
<tr>
<td>Qlaira®</td>
<td>162</td>
<td>6.9</td>
<td>4.7</td>
<td>3.7</td>
<td>2.8</td>
</tr>
<tr>
<td>Midiana®</td>
<td>70.5</td>
<td>3.2</td>
<td>2.1</td>
<td>1.6</td>
<td>1.2</td>
</tr>
<tr>
<td>Logest®</td>
<td>78</td>
<td>3.3</td>
<td>2.3</td>
<td>1.8</td>
<td>1.0</td>
</tr>
<tr>
<td>Novynette®</td>
<td>70.5</td>
<td>3.2</td>
<td>2.1</td>
<td>1.6</td>
<td>1.2</td>
</tr>
<tr>
<td>Artizia®</td>
<td>54</td>
<td>2.3</td>
<td>1.6</td>
<td>1.2</td>
<td>0.9</td>
</tr>
<tr>
<td>Angeliq</td>
<td>181.5</td>
<td>7.8</td>
<td>5.3</td>
<td>4.1</td>
<td>3.2</td>
</tr>
<tr>
<td>Rigevidon®</td>
<td>66</td>
<td>2.8</td>
<td>1.8</td>
<td>1.4</td>
<td>1.0</td>
</tr>
<tr>
<td>Progestone only pills</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lactinet®</td>
<td>136.5</td>
<td>5.8</td>
<td>4.0</td>
<td>3.1</td>
<td>2.3</td>
</tr>
<tr>
<td>Emergency contraception</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postinor®</td>
<td>132</td>
<td>5.6</td>
<td>3.9</td>
<td>3.0</td>
<td>2.2</td>
</tr>
<tr>
<td>Escapelle®</td>
<td>164</td>
<td>7.0</td>
<td>4.8</td>
<td>3.7</td>
<td>2.9</td>
</tr>
<tr>
<td>IUDs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yunona® T cu</td>
<td>4.4</td>
<td>0.2</td>
<td>0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>Yunona® Bio T</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yunona® bio multi</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yunona® T super</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IUD generic Chinese</td>
<td>0.6</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>Mirena®</td>
<td>37.2</td>
<td>1.6</td>
<td>1.1</td>
<td>0.8</td>
<td>0.6</td>
</tr>
</tbody>
</table>

---

Segments of the population which are disadvantaged and high priority for the provision of modern contraceptives

The case for subsidizing the provision of family planning in Moldova

The prevention of unintended pregnancies should be a priority in modern societies. Women empowerment, employment and integration - are crucial elements for the wellbeing of women and of society as a whole, particularly in the current economic climate. It is therefore crucial that decision makers and competent authorities, include modern contraceptive choice as a key component of integrated policies, in the areas of sexual and reproductive health, gender equality, women empowerment, family planning, employment and education.

There are important cost implications to providing contraceptive services to the increasing number of women needing modern contraceptives, and to offering comprehensive, high-quality services to all users. At the same time, money spent on contraceptive services to help women avoid unintended pregnancies has large health, social and economic benefits for women, families and society, and results in net savings to the health care system. The benefits of practicing contraception are broad, spanning social, economic and health outcomes, and they stem from women’s and couples’ ability to achieve the size of family they want, time their pregnancies to fit their lives, reduce maternal mortality and morbidity, and provide their infants with the best chances for health and well-being. Moreover, real success should ultimately be measured in terms of important health outcomes, including better birth spacing, reductions in adolescent pregnancy and early childbearing, and reductions in unintended pregnancy and unsafe abortion, leading to improved maternal health and child survival. Limiting access to modern contraception does not result in increased fertility, as women with an unplanned pregnancy frequently resort to unsafe abortion. There is good evidence that increased access to modern contraception leads to decreasing rates of induced abortion. In addition, the use of condoms is effective in preventing sexually transmitted infections, including HIV.

Ability to pay analyses and follow-up of these analyses

The scope of this ability to pay analysis was not intended to be comprehensive, or final. Rather, it is intended to be one examination, among several, that seek to support a broader range of contraceptive supply initiatives. Incomes, prices, and the accuracy of data change. Therefore, analyses regarding pricing, affordability, and willingness to pay should be regularly performed.

Specific findings: ability to pay analyses

Table 5 indicates how a total market approach (TMA) to the provision of modern contraceptives might provide for different segments of the population.

- Q1 and Q2 – the poorest 40 percent of the population—can afford the cheapest condoms, but none of the available oral combined hormonal contraceptives, progesterone only pills, or emergency contraception, on a regular basis. However they could afford most types of copper T IUDs. These IUDs in terms of cost per CYP are significantly less expensive, than

---

any other available method of modern contraception. The poorest forty percent segment
of the population is estimated to include 281,622 women aged 15 to 49 years.

- For Q3 and Q4 - the cheaper condoms are affordable, as well as the cheapest oral pills, in addition to IUDs.
- Even most couples in Q5, the richest 20 percent of the population, probably find it difficult to pay for the more expensive oral contraceptives (Yasmin®, Yaz®, Belara®, Angeliq and Qlaira®), on a regular basis. Most vaginal foams, cervical hormonal rings and brands of emergency contraception are too expensive, even for the richest 20 percent segment, on a regular basis.
- There is scope for extended commercial sales of several of cheaper brands of oral contraceptives. There is potential for commercial pharmacies for expansion of their market sales to the most affluent 20 percent of the population. This would be partly dependent on good objective promotion.
- Higher-priced oral pills are unaffordable to middle-income earners (Q3), and even many high earners (Q4 and Q5). There is a possibility that the commercial sale of cheaper CoCs and progesterone only pills, could be extended further to Q3 – the middle income earners.
- Copper T IUDs are the least expensive of all types of contraceptive method.
- Free public sector contraceptives should possibly be targeted to the bottom 40 percent of the population.

Recommendations for meeting the contraceptive needs of different segments of the population and particularly the most vulnerable ones

Issues related to registration of contraceptives and the availability of contraceptives through the National Health Insurance Company

This overall market segmentation research has confirmed that several segments of the population, who have a high need for family planning, cannot afford commercially available modern contraception. Generally, there is a substantial level of unmet need for modern contraception in the country and the ability to pay for this is for almost all couples extremely limited. But there are certain groups who are particularly vulnerable and specifically marginalized, and have significantly higher unmet need. This applies particularly to the poorest forty percent segment of the population.

In order to increase the availability of modern contraception, it is important that choice is extended, and particularly by making available more long term hormonal contraceptive methods. Specifically urgent consideration should be given to taking steps to encourage the registration and availability of two long acting contraceptives - i.e. injectable medroxyprogesterone acetate (Depo-Provera®) and hormonal implants (the two most common versions are - the single-rod etonogestrel implant, and the two-rod levonorgestrel implant). The introduction of hormonal implants would have to be accompanied by a programme to train family doctors and gynecologists in their insertion and removal.

---

80 Figure from the 2014 population census. See NBS website http://www.statistica.md/pageview.php?l=ro&idc=479
It is understood that medroxyprogesterone acetate was registered in the country until 2007. At this time UNFPA donated appreciable quantities of this injectable hormonal contraceptive for vulnerable people. We understand that medroxyprogesterone acetate has been imported in 2017 by Gideon Richter, probably through an arrangement with a Romanian subsidiary. The MoH might be able to make a special arrangement for importing medroxyprogesterone acetate via a Romanian pharmaceutical firm. If such an arrangement is made, it would be important that the package insert is in Romanian, and probably Russian.

The NHIC has high coverage of the population, but does not include any modern contraceptives in the list of pharmaceuticals eligible for reimbursement. It is strongly recommended that the NHIC includes in the list of reimbursable medicines - a limited number of modern contraceptives. Particularly for couples in the more affluent 60 percent segments of the population, the NHIC should include two of the lower cost combined hormonal oral contraceptives, e.g. Microgynon® - Bayer (30 mcg Ethinylestradiol and 150 Levonorgestrel) and Regulon® – Gideon Richter (Ethinylestradiol 0.03 mg, desogestrel 0.15 mg), and possibly an emergency contraceptive (Levonorgestrel 1.5 mg) and a copper T IUD. When medroxyprogesterone acetate and hormonal implants are registered in the country, than these should also be included on the NHIC’s list of reimbursable pharmaceuticals.

The level of reimbursement should be decided by the appropriate committee, but initially could be set at 70 percent, and the coverage and financial cost, be reviewed after one year. When the procurement of modern contraceptive for vulnerable groups of population will be realised from the State Budget within the National Programme on Sexual and Reproductive Health and Rights 2018-2022, then this will mean there will be no need to use any of funds provided by the NHIC to primary health care facilities for purchase of contraceptives for vulnerable groups. This would provide cost-saving to the NHIC, which could be used for reimbursement of contraceptives, by means of including a number of modern contraceptives on the NHIC’s reimbursable drugs list.

**Provision of modern contraceptives for vulnerable populations**

The Ministry of Health in Order No 658 of the 18 August 2015 has already identified seven ‘vulnerable’ groups who warrant the provision of free modern contraceptives, and this market segmentation study confirms these groups (sexually active adolescents, persons with low incomes - an income lower than the minimum consumer basket for each family member, HIV positive persons, persons who abusively consume alcohol and illegally use drugs and other psychotropic substances, registered with the addictionologist, people with mental health problems, registered with the psychiatrist and family doctor, victims of sexual abuse, women who aborted during the last year).

There have been suggestions that an additional group of people with disabilities should also be included in the population defined as vulnerable81. They certainly have many characteristics of vulnerable or marginalized, but although the Ministry of Labor, Social Protection and Family has figures on some of these people, they are not readily available. It is suggested that efforts are made to clarify what disabilities would be appropriate to include in the vulnerable group and what numbers are involved.

---

The following are the identified vulnerable groups agreed by the MoH and for each of them estimates of the likely numbers in each group are given with suggestions on the most appropriate form of modern contraception. The source for these estimates and suggestions are indicated.

1. **Sexually active adolescents.** Information from a survey carried out in 2015 provided information on the proportion of adolescents who are sexually active. This was supported by the MoH, WHO, and the Swiss Agency for Development and Cooperation and collected figures on behavioural and social determinants of adolescent health. The survey found that about 40 percent of 17 year olds are sexually active\(^82\). This suggests that about 90,000\(^83\) adolescent boys and girls are sexually active. WHO\(^84\) and other authorities\(^85, 86\) indicate the most commonly used contraceptive among adolescents is the male condom, but it is important that emergency contraception is available, as well as other modern contraceptives, particularly long acting ones such as - IUDs and medroxyprogesterone acetate (MPA), and combined oral hormonal pills are appropriate for some of this group.

2. **Persons with low incomes (an income lower than the minimum consumer basket for each family member).** It is difficult to estimate the number of people that fall into this category. From discussions with the staff of the Ministry of Labor, Social Protection and Family it is clear that this Ministry has established procedures to review the economic situation of vulnerable people, and this is undertaken principally together with rayon based social workers. However the Ministry was not able to provide numbers for people categorized as receiving economic and social support. They agreed that while the proportion of the population living in poverty has fallen from a high of 30.2 percent of the population in 2006 to 11.4 percent in 2014 (latest figure)\(^87, 88\) and this means that over one in 10 families continue to be below the nationally defined poverty level; however they estimated only about five percent of families and consequently women of reproductive age might be classified as in receipt of social support. This would suggest a figure of about 35,203 women in this group. We were informed by many health workers in our visits to several rayons in the country that family doctors with, if necessary, the assistance of the rayon social worker would know who was receiving social support, and thus eligible for free contraceptives. WHO and other experts do not provide specific advice on which contraceptives might be appropriate for this group of women, but imply long acting methods, such as medroxyprogesterone acetate (MPA) and IUDs, would be a higher priority, than oral hormonal pills or other methods.

3. **HIV positive persons.** There are several estimates of the numbers of people aged 15 to 49 years living with HIV. UNAIDS estimates this figure to be 18,000\(^89\). However at the end of 2016 there were only 7,906 people living with HIV registered in the country (5,340 people on the right bank and 2,566 on the left bank of Nistru)\(^90\). An estimate between

---


\(^{86}\) Faculty of Sexual and Reproductive Healthcare. Contraceptive Choices for Young People Clinical Effectiveness Unit. London: March 2010.


these two is 11,043\textsuperscript{91}. WHO recommends that “women taking any nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) can use all hormonal contraceptive methods without restriction: combined oral contraceptive pills (COCs), contraceptive patches and rings, combined injectable contraceptives (CICs), progestogen only pills (POPs), progestogen-only injectables (DMPA and NET-EN), and levonorgestrel (LNG) and etonogestrel (ETG) implants”\textsuperscript{92}. Probably long acting contraceptive methods are most appropriate for these people, and sexually active HIV positive men and women should also use condoms.

4. **Persons who abusively consume alcohol and illegally use drugs and other psychotropic substances, registered with the addictionologist.** The most recent national estimate of the population of injecting drug users (e.g. people who have injected drugs in the past 12 months) was obtained in 2009–10 and “together with the estimate derived from narcological registers in all cities, harm reduction programmes and human immunodeficiency virus (HIV) testing among the population of injecting drug users from integrated bio-behavioural studies suggests that around 31,600 injecting drug users live in the Republic of Moldova”\textsuperscript{93}. The sex ratio is around 44 percent female and 56 percent male. It is suggested that long acting methods, such as medroxyprogesterone acetate (MPA) and IUDs, would be a higher priority than oral hormonal pills, together with male condoms\textsuperscript{94}.

5. **People with mental health problems, registered with the psychiatrist and family doctor.** Information on people with alcohol and psychiatric problems is not readily available, although we asked people at the Ministry of Health, as well as at the Ministry of Labor, Social Protection and Family for figures. We were advised that social workers and family doctors at the rayon level would know these people. It is estimated that around 3,500 WRA might be in these categories. It is recommended that long acting methods such as medroxyprogesterone acetate (MPA) and IUDs would be a higher priority than oral hormonal pills or other methods\textsuperscript{95}.

6. **Victims of sexual abuse**\textsuperscript{96}. The number of women subjected to sexual abuse is considerable. At the present time it is only possible to concentrate on those who are most severely affected and who seek refuge, but efforts should be made to obtain figures for women reporting such abuse to the police. There are 14 shelters in Moldova for women who have suffered domestic and other violence, with a capacity of 181 places. There are an average of 314 monthly beneficiaries of these shelters i.e. 3,768 per annum\textsuperscript{97}. Long acting forms of contraception such as - MPA injection or an IUD are recommended for the longer term, and emergency contraception if necessary, for the initial contact with health services\textsuperscript{98}.

7. **Women who aborted during the last year.** The Reproductive Health Training Center (RHTC) together with the MoH maintains a monitoring system for induced abortions and the coverage of these statistics is considered to be high. Based on this system, it is


estimated that the annual abortion rate is 15 abortions per 1,000 women aged 15 to 49 years, or 12,635 per year. Once again, long acting forms of contraception such as MPA injection, or an IUD are the most appropriate contraceptives for this group of women, but other contraceptives are not contraindicated. Contraception can be initiated immediately post-abortion and all contraceptive options may be used, but longer term methods including IUDs, injectable hormonal contraception and implants are probably the most appropriate.\footnote{WHO. Health worker roles in providing safe abortion care and post-abortion contraception. Geneva: WHO, 2015.}

The draft ‘National Program on Sexual and Reproductive Health and Rights (NPSRHR)’\footnote{Government of the Republic of Moldova. National Program on sexual and reproductive health and rights 2017-2021. Draft. Chisinau: no date.} for the years 2018 to 2022 is due to be submitted by the MOH for consideration to the national Government. One of the aims of this Program is to provide modern contraceptives for the seven vulnerable groups mentioned earlier. The Program would have an annual budget line equivalent to €300,000 for the purchase of modern contraceptives.

As part of the provision of PHC services, an indicator has been agreed to assess progress to achieving coverage of contraceptives for these vulnerable groups - the indicator of the percentage of at risk women aged up to 35 and vulnerable groups receiving modern contraceptives. It is intended that the indicator acts as an incentive to PHC facility managers, as part of the performance-based incentive scheme in primary health care, introduced with aim to improve PHC performance. Fifteen percent of the PHC facilities budget is to be provided by NHIC to the respective PHC institutions based on the level of achievement of a number of performance indicators. However the FP indicator lacks precision and it will be difficult to obtain consistently reliable figures. And this was the situation found at the various PHC facilities visited during this mission.

Forecasting contraceptive needs for the vulnerable population use and estimating costs

To estimate future consumption of contraceptives, it is useful to have past consumption data to establish a trend. This data usually takes the form of contraceptive logistics data, from a logistics management information system (LMIS). In Moldova only a partial LMIS exists. Health facilities simply refer patients, usually with a prescription, to commercial pharmacies to purchase contraceptives and this ‘use’ is not adequately captured in any reporting.

Because actual past consumption data is not available, this forecasting of modern contraceptive needs - used demographic or population data to estimate future contraceptive requirements. The forecasts made here are dependent upon making informed assumptions regarding future CPR for the various vulnerable groups. Using 2012 baseline data from the MICS, including CPR, possible consumption estimates have been developed for the seven priority segments of the vulnerable population. The estimates also take into account informed assumptions from the people met during this consultancy about likely changes in CPR and method mix, and information on what are appropriate contraceptives for the different groups.
Table 6 gives cost figures for different modern contraceptives, if obtained from the UNFPA Procurement Services\textsuperscript{101}. This service is available to governments and other organisations, the procedures are relatively straightforward (see https://www.unfaprocurement.org/order ).

Table 6: Indicative international prices for procuring a range of modern contraceptives

<table>
<thead>
<tr>
<th>Contraceptive method</th>
<th>Unit</th>
<th>Average cost per unit/set/cycle/pack/vial (US$)</th>
<th>Quantity required per couple year of protection (CYP)</th>
<th>CYP conversion factor</th>
<th>Cost per CYP (US$)</th>
<th>Cost per CYP (€)\textsuperscript{102}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male condom</td>
<td>Gross</td>
<td>3.15</td>
<td>120 items</td>
<td>0.83</td>
<td>2.61</td>
<td>2.32</td>
</tr>
<tr>
<td>IUD Copper\textsuperscript{103}</td>
<td>Set</td>
<td>0.317</td>
<td>4.6 CYP per IUD inserted</td>
<td>0.22</td>
<td>0.07</td>
<td>0.06</td>
</tr>
<tr>
<td>Progestagen only pill</td>
<td>Cycle</td>
<td>0.90</td>
<td>15 cycles</td>
<td>15</td>
<td>13.5</td>
<td>12.00</td>
</tr>
<tr>
<td>Combined low dose pill (\text{Microgynon}^{30'})</td>
<td>Cycle</td>
<td>0.78</td>
<td>15 cycles</td>
<td>15</td>
<td>11.7</td>
<td>10.39</td>
</tr>
<tr>
<td>Emergency pill</td>
<td>Pack</td>
<td>0.25</td>
<td>20 doses</td>
<td>20</td>
<td>5</td>
<td>4.44</td>
</tr>
<tr>
<td>Injectable contraceptive</td>
<td>Vial</td>
<td>0.758</td>
<td>4 doses</td>
<td>4</td>
<td>3.03</td>
<td>2.69</td>
</tr>
<tr>
<td>Subdermal implants</td>
<td>Set</td>
<td>8.50</td>
<td>3.8 CYP per implant</td>
<td>0.26</td>
<td>2.21</td>
<td>1.96</td>
</tr>
</tbody>
</table>


\textsuperscript{101} See: https://www.unfaprocurement.org/products accessed 6 June 2017

\textsuperscript{102} A conversion rate of US$ 1 = € 0.9144 was used; http://www.xe.com/ accessed May 2017

\textsuperscript{103} 3.3 CYP for 5 year IUD, e.g. LNG-IUS)
Table 7: Vulnerable priority segments of the population for provision of free family planning, projections for 2018 including indicative costs

<table>
<thead>
<tr>
<th>Priority group</th>
<th>Numbers of women (unless stated otherwise)</th>
<th>Contraceptive methods to be included (method mix)</th>
<th>Indicative costs UNFPA Procurement prices(^{104}) €</th>
<th>Indicative costs at existing pharmacy prices(^{105}) €</th>
<th>How contraceptives might be delivered</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) Sexually active adolescents aged 15 to 19 years</td>
<td>90,000</td>
<td>Condoms (50%), CoCs (15%), IUDs (15%), and emergency contraception (20%). MPA to be included when available</td>
<td>325,395</td>
<td>3,430,350</td>
<td>Ministry of Health through Youth Friendly Health Centres and Family Doctors from PHC facilities and rayon gynaecologists from RH Cabinets</td>
</tr>
<tr>
<td>2) Low income families</td>
<td>35,203</td>
<td>CoCs (20%), IUDs (60%) and condoms (20%). MPA and implants to be included when available</td>
<td>90,758</td>
<td>285,160</td>
<td>Ministry of Health, through Family Doctors from PHC facilities in conjunction with social workers, and rayon gynaecologists from RH Cabinets</td>
</tr>
<tr>
<td>3) HIV positive people who know their status(^{106})</td>
<td>11,043(^{107})</td>
<td>CoCs (50%), IUDs (40%), emergency contraception (10%). MPA and implants to be included when available. It is assumed condoms are provided by GFATM for all HIV positive people</td>
<td>73,974</td>
<td>355,453</td>
<td>Ministry of Health through Family Doctors from PHC facilities, rayon gynaecologists and NGOs working with PLHIV.</td>
</tr>
</tbody>
</table>

\(^{104}\) UNFPA Product Catalog. [https://www.unfpaprocurement.org/products](https://www.unfpaprocurement.org/products) accessed 6 June 2017

\(^{105}\) Cheapest CoCs, condoms, EC and IUDs available in commercial pharmacies see Table 4

\(^{106}\) Assumption most are aged 15 to 49 years

4) People with alcohol, other drug problems, who are registered with an addictologist

| People with alcohol, other drug problems, who are registered with an addictologist | 31,600<sup>108</sup> | IUDs (60%), CoCs (30%), condoms (10%), MPA and implants to be included when available | 106,966 | 404,796 | Ministry of Health, through Family Doctors from PHC facilities and rayon gynaecologists from RH Cabinets

5) People registered with psychiatrist

| People registered with psychiatrist | 3,500 | IUDs (60%), CoCs (30%), and condoms (10%). MPA and implants to be included when available | 11,848 | 44,835 | Ministry of Health through Family Doctors from PHC facilities and rayon gynaecologists from RH Cabinets, as well as through Community Mental Health Centers

6) Women suffering domestic violence and in refuges

| Women suffering domestic violence and in refuges | 3,768 | Emergency contraception (30%), IUDS (60%), CoCs (10%). MPA and implants to be included when available | 9,070 | 164,655 | Through the MLSPF social workers, Family Doctors from PHC facilities and rayon gynaecologists from RH Cabinets and NGOs providing assistance to survivors of domestic violence

7) Women having had an abortion in previous year

| Women having had an abortion in previous year | 12,635 | IUDs (70%), CoCs (30%). MPA and implants to be included when available | 39,919 | 147,470 | Rayon gynaecologists from RH Cabinets, hospitals and other units performing abortions

| Total costs | | | 657,930 | 4,832,719 |

---

<sup>108</sup> Assumption that most are aged 15 to 49 years
Given that there is no existing consumption data for modern contraceptives for vulnerable groups in Moldova, to base projections for the future, initial estimates should be treated as tentative.

These prices are less than a seventh of those available at the present time for similar contraceptives in commercial pharmacies in Moldova.

Indicative international prices (see Table 6) have been applied to the different scenarios, as set out in Table 7. The mix of methods has been suggested which is likely to be most appropriate for the different segments; for instance for ‘sexually active adolescents’ - a mix of condoms (60%), emergency contraception (20%) and CoCs (15%); and for low income families - CoCs (20%), IUDs (60%) and condoms (20%)

Building on the identification of the disadvantaged segments for high priority for provision of modern contraception, it is possible to propose several scenarios that might warrant the provision of free family planning. In most of these scenarios, the segments will, to a varying extent, overlap. Thus for instance, low income families will necessarily include HIV positive people and people with alcohol, and other drug problems. However, initially considering the different segments separately highlights the cost of providing contraceptives for each segment. The prices used to cost the procurement of different contraceptives are based on current May 2017 international tender costs from UNFPA (see Table 6).

The development of more sophisticated demographic-based forecasts requires numerous calculations to predict consumption patterns. Assumptions made to develop the following forecasts will need to be regularly re-examined, in the light of any additional data, notably accurate logistics-based consumption figures, when they become available.

The costs of providing modern contraceptives for WRA in low income families are estimated to be €90,758, if the contraceptives are procured from UNFPA Procurement Services, and €285,160 if they were purchased from local pharmacies; and for women following an abortion €39,919 from UNFPA Procurement Services, and €147,470 from local pharmacies. Similar comparisons are given for all seven priority vulnerable segments.

The total cost of providing complete coverage for all these seven groups is estimated to be considerably more than is proposed in the draft National Program on Sexual and Reproductive Health and Rights 2018-2022, that includes an Estimated Budget with a separate Budget line for the procurement of modern contraceptives for vulnerable groups (equivalent to €300,000 per year). When approved by the Government – this amount will be available from State Budget for the procurement of modern contraceptives in the period 2018-2022. According to the estimations reflected in Table 7 of this report – the proposed €300,000 per year will not cover the needs of all those in the seven categories of vulnerable people, but at the initial stage it is worth starting at least with €300,000 per year allocated for procurement of modern contraceptives for vulnerable groups from State Budget. When the logistic management information system is established and well-functioning, then the efforts to increase the budget allocation for the procurement of modern contraceptives for vulnerable groups from State Budget can be attempted.

---

Consequently, for the possible seven priority groups for receiving free contraceptives, it will be best, if modern contraceptives are provided by the Ministry of Health, via the NPSRHR 2018-2022. This will need detailed careful planning, including the establishment of a reliable computerized contraceptive Logistics Management Information System (LMIS). This would allow estimating, procuring and the requisitioning of contraceptives, based on the consumption of contraceptives over the previous three months. It would also allow the monitoring of stock levels in all primary healthcare facilities.

**Roadmap for implementation of the Total Market Approach**

There is a clear case for improving access to modern contraceptives to all segments of the population in Moldova. Use of contraceptives has declined over the past 20 years from just over a half of married women to 42 percent. Unmet need for contraception has increased over this time and is high at 27 percent and even higher at 35 percent when all women of reproductive age are considered\(^{110}\).

The prevention of unintended pregnancies should be a priority in modern societies, and enabling people to choose if, when they become pregnant, and how many children they have - is a basic right. Women empowerment, employment and integration are crucial elements for the wellbeing of women and of society as a whole, particularly in the current economic climate. It is therefore crucial that decision makers and competent authorities include modern contraceptive choice as a key component of integrated policies in the areas of sexual and reproductive health.

There are important cost implications to providing contraceptive services to the increasing number of women needing modern contraceptives, and to offering comprehensive, high-quality services to all users. At the same time, money spent on contraceptive services to help women avoid unintended pregnancies has large health, social and economic benefits for women, families and society, and results in net savings to the health care system.

This market segmentation analysis for modern contraceptives in Moldova has shown that the market is divided into several segments and to meet the various requirements of these different segments, a total market approach is required. These need co-ordinated actions on the part of the public sector (principally the Ministry of Health and as part of that, the Medicines and Medical Devices Department; and also the Ministry of Labor, Social Protection and Family), parastatal organisations (specifically the National Health Insurance Company), non-governmental organisations (such as Reproductive Health Training Centre), pharmaceutical companies (including Bayer Pharmaceuticals, JV “RihPanGalFarma” Ltd. and the Joint Stock Company "MoldFarm), pharmaceutical wholesalers (e.g. Sanfarm-Prim S.A.), commercial pharmacies (such as Felicia, Hippocrates, Farmacia Familiei and Odeon). And importantly medical and pharmacy undergraduate, postgraduate and continuing education establishments (particularly the Obstetrics and Gynaecology Departments, the Family Medicine Department, the Center for Simulation in Medical Training of the State Medical and Pharmaceutical University “Nicolae Testemitanu”\(^{2}\)), have a crucial role in achieving improved family planning care.

---

The Government (Ministry of Health) should as a matter of urgency establish a statutory technical group to develop a plan for the phased transition of the country to a total market approach, to the provision of modern contraceptives.

**Specific issues which need early attention**

- Steps should be taken to explore how the two long-term contraceptives (medroxyprogesterone acetate injection and either the single-rod etonogestrel implant, or the two-rod levonorgestrel implant) can be registered in the country, and a commercial pharmaceutical company persuaded to import and market them. They should of course be made available through the Ministry of Health’s National Program on Sexual and Reproductive Health and Rights 2018-2022. It will be necessary to support training programmes for family doctors and gynaecologists in insertion and removal of hormonal implants.

- Representation should be made to the National Health Insurance Company for consideration to be given, to placing a limited number of modern contraceptives on the list eligible for medicines reimbursement e.g. Microgynon® - Bayer (30 mcg Ethinylestradiol and 150 Levonorgestrel) and Regulon® – Gideon Richter (Ethinylestradiol 0.03 mg, Desogestrel 0.15 mg), and possibly an emergency contraceptive (Levonorgestrel 1.5 mg) and a copper T IUD. When Medroxyprogesterone acetate and hormonal Implants are registered in the country, than these should also be included on the NHIC’s list of reimbursable pharmaceuticals. Once these are registered, and if they were included in the reimbursement list of pharmaceutical, then pharmaceutical companies have indicated, this would be an incentive for them to import them.

- Discussion should be had with representatives of pharmaceutical companies, importers and wholesalers of contraceptives and commercial pharmacies, to market and promote cheaper combined hormonal contraceptives. In addition continuing education initiatives, involving family doctors and gynaecologists, should be based on objective evidence, regarding different types of hormonal combinations, and the absence of any discernible difference between them.

- The draft NPSRHR 2018-2022 is at significant and far sighted development. It includes an Action Plan, a Monitoring and Evaluation Framework and a Costed Budget and the Ministry of Health needs to follow through with its implementation after approval. This should include acquiring expertise in estimation, procurement, distribution and monitoring of implementation. The establishment of a contraceptive logistics management information system is crucial for the effectiveness of the Program. The draft National Programme on Sexual and Reproductive Health includes an estimated Budget with a separate budget line for the procurement of modern contraceptives for vulnerable groups - equivalent to €300,000 per year. When approved by the Government – this amount will be available from the State Budget for the procurement of modern contraceptives in the period 2018-2022. According to the estimation reflected in Table 7 of this report – the €300,000 per year will not cover the needs of all people from those seven categories of vulnerable groups, but in the initial stage it is worth to start with at least the €300,000 per year allocated for procurement of modern contraceptives for vulnerable groups. When the logistic management information system is established and well-functioning, then the efforts to increase the budget allocation for the procurement of modern contraceptives for vulnerable groups from State Budget can be attempted.
An information, education and communication campaign will be necessary to explain the objectives of the National Program on Sexual and Reproductive Health and Rights 2018-2022 and who (the vulnerable groups) is entitled to free contraceptives, and where they are available. This should include pamphlets and posters to be displayed at appropriate MoH facilities.

At a later stage, consideration might be given to establishing a social marketing programme for condoms, and even of an oral contraceptive pill. For this to happen, initially it would be useful to arrange a visit to the social marketing programme in Romania.

Monitoring of implementation of the total market approach, will be important to assess if it meeting its objectives. This could include periodic surveys of who is receiving contraceptives, from where and whether they are covered by the NHIC reimbursement scheme, or covered with free contraceptives under the NPSRHR 2018-2022, or a purchasing them. The last Multiple Indicator Cluster Survey was carried out in 2012 and apparently a decision has not yet been taken on when, or if a further MICS will be undertaken, but there is a suggestion that it might be replaced by a mini-MICS. It is not clear what this might cover, but it is important if one is carried out, that it should include questions on contraceptive use, unmet need and supply and source of contraception.

Activities which UNFPA could consider supporting the Government to strengthen family planning

It is suggested that UNFPA might consider providing assistance in: the development of standard care protocols (based on WHO’s Eligibility criteria for Contraceptive Use) and one sheet algorithms for family doctors for different contraceptives in Romanian and Russian; training in estimation of contraceptive needs; training on establishing and running a contraceptive LMIS; training on modern contraceptive technology; training on IUD insertion and use of Implants; development, printing and distribution of information posters, explaining eligibility for specific contraceptives, under the NHIC and for vulnerable people under the MoH’s National SRHR Programme 2018-2022.

---


References

13. IPPF affiliate. Societatea de Planificare a Familiei din Moldova
22. Ministry orders: Chisinau municipality, Nr. 144, 28/02/2011, on essential drug
24. Ministry orders: Nr. 600/320 of 07.24.2015 on the mechanism for including medicines for compensation from the compulsory health insurance funds
25. Ministry orders: Order nr. 600/320 of 07.24.2015 on the mechanism for including medicines for compensation from the compulsory health insurance funds
28. Ministry of Health. Order nr 658. 18.08.2015. Regulation on Providing Contraceptives to Vulnerable Groups, procured at the level of primary health care from the compulsory health insurance funds.
35. Parliament law nr. 138 15.06.2012 on reproductive health


Appendix 1: Draft Agenda. In-country mission of Dr. Godfrey Walker, UNFPA International Expert to conduct the Market Segmentation Analysis for Modern Contraceptives in the Republic of Moldova

<table>
<thead>
<tr>
<th>Time</th>
<th>Activities</th>
<th>Address</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.05.2017 (Monday)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrival to Chisinau International Airport (RO209 OTP-KIV at 22:30 p.m.)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.05.2017 (Tuesday)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 9:00 – 10:30      | Meeting at the UNFPA Moldova CO                                           | Chisinau, 31 August, 131 Str.                    | Dr. Rita Columbia, UNFPA Representative in the Republic of Moldova  
Dr. Godfrey Walker, UNFPA International Expert  
Ms. Eugenia Berzan, Programme Analyst RH and Youth  
Ms. Victoria Docițcu, Programme Associate RH and Youth |
| 11:00 – 11:45     | Meeting with Deputy Minister of Health, Dr. Liliana Iașan                 | Chisinau, 2, V. Alecsandri Str.                   | Dr. Rita Columbia, UNFPA Representative in the Republic of Moldova  
Dr. Godfrey Walker, UNFPA International Expert  
Ms. Eugenia Berzan, Programme Analyst RH and Youth  
UNFPA Moldova Translator |
| 11:45 – 12:30     | Meeting with Dr. Maria Lăpteanu, Head of Medicines and Medical Devices Department, MoH | Chisinau, 2, V. Alecsandri Str.                   | Dr. Godfrey Walker, UNFPA International Expert  
Dr. Eugenia Berzan, Programme Analyst RH and Youth  
UNFPA Moldova Translator |
| 12:30 – 13:30     | Lunch break                                                               |                                                   |                                                                                                                                                                                                            |
| 13:30 – 14:30     | Meeting with Dr. Tatiana Zătic, Head of Primary, Emergency and Community Health Care Department, MoH | Chisinau, 2, V. Alecsandri Str.                   | Dr. Godfrey Walker, UNFPA International Expert  
Dr. Eugenia Berzan, Programme Analyst RH and Youth  
UNFPA Moldova Translator |
| 14:30 – 15:00     | Meeting with Dr. Natalia Popa, Deputy Head of Hospital Healthcare Department, MoH | Chisinau, 2, V. Alecsandri Str.                   | Dr. Godfrey Walker, International Consultant  
Dr. Eugenia Berzan, Programme Analyst RH and Youth  
UNFPA Moldova Translator |
| 15:00 – 15:30     | Meeting with Mr Denis Valac, Head of Budget, Finance and Insurance Department, MoH | Chisinau, 2, V. Alecsandri Str.                   | Dr. Godfrey Walker, UNFPA International Expert  
Dr. Eugenia Berzan, Programme Analyst RH and Youth  
UNFPA Moldova Translator |
| 16:00 – 16:45     | Meeting with Dr Vladislav Zara, General Director of the Agency of Medicines and Medical Devices (as well as with Mr. Adrian Scripcari, Head of Certification, homologation and registration division, Department of Medical Devices and Ms Tamara Chetrari, Head of | Chisinau 2/1 Korolenko Str.                        | Dr. Godfrey Walker, UNFPA International Expert  
Ms. Eugenia Berzan, Programme Analyst RH and Youth  
Translator |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45-17:30</td>
<td>Meeting with Mr. Ivan Antoci, Director of Center for Centralized Public Procurements in Health (as well as with Ms. Raisa Golovei, Head of Medicines Procurement Division and Mr. Eduard Țernă, Head of Medical Devices Procurement Division)</td>
<td>Chisinau, 2/1 Korolenko Str.</td>
<td>Dr Godfrey Walker, UNFPA International Expert Ms Eugenia Berzan, Programme Analyst RH and Youth Translator</td>
</tr>
<tr>
<td>17.05.2017</td>
<td><strong>Wednesday</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 – 10:00</td>
<td>Meeting with Mr. Dumitru Parfentiev, General Director of the National Health Insurance Company (as well as with Mr. Ghenadie Damașcan, Head of Contracting and Relations with Providers Department)</td>
<td>Chisinau, 46, Vlaicu Pircalab str.</td>
<td>Dr. Rita Columbia, UNFPA Representative in the Republic of Moldova Dr Godfrey Walker, UNFPA International Expert Ms Eugenia Berzan, Programme Analyst RH and Youth Translator</td>
</tr>
<tr>
<td>10:30-11:30</td>
<td>Meeting with Mr. Stefan Harea, General Director of the Pharmaceutical Storage “Sanfarm-Prim” S.A.</td>
<td>Chisinau, 149 A, Grenoble Str.</td>
<td>Mr Godfrey Walker, UNFPA International Expert Ms Eugenia Berzan, Programme Analyst RH and Youth Translator</td>
</tr>
<tr>
<td>11:30-13:00</td>
<td>Lunch break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00-13:45</td>
<td>Meeting with Mr Tudor Crigan, Director of the Joint Stock Company &quot;MoldFarm&quot;</td>
<td>Chisinau 3, Cosmescu Str.</td>
<td>Dr Godfrey Walker, UNFPA International Expert Ms Eugenia Berzan, Programme Analyst RH and Youth Translator</td>
</tr>
<tr>
<td>14:15-15:30</td>
<td>Meeting with Dr Sergiu Gladun, Director of Mother and Child Institute (as well as with Dr Mihail Strătilă, Head of Reproductive Health and Medical Genetics Center, Mother and Child Institute and Dr. Victoria Ciubotaru, Scientific Researcher, Reproductive Health and Medical Genetics Center)</td>
<td>Chisinau, 93, Burebista Str.</td>
<td>Mr Godfrey Walker, UNFPA International Expert Ms Eugenia Berzan, Programme Analyst RH and Youth Translator</td>
</tr>
<tr>
<td>16:00-17:00</td>
<td>Meeting with Dr. Rodica Comendant, Director of NGO “Reproductive Health Training Centre” (RHTC)</td>
<td>Chișinău, 20, Melestiu Str.</td>
<td>Mr Godfrey Walker, UNFPA International Expert Ms Eugenia Berzan, Programme Analyst RH and Youth Translator</td>
</tr>
<tr>
<td>18.05.2017</td>
<td><strong>Thursday</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00- 10:00</td>
<td>Departure to Cimislia district</td>
<td>8:00- 10:00</td>
<td>Departure to Cimislia district</td>
</tr>
<tr>
<td>10:00-12:00</td>
<td>Meeting with Dr. Ludmila Capcelea, Manager of Health Center. Visiting the Health Center from Cimislia, including the Cimislia district 135, Alexandru cel Bun Str.</td>
<td>Cimislia district 135, Alexandru cel Bun Str.</td>
<td>Dr. Rita Columbia, UNFPA Representative in the Republic of Moldova Ms Ganna Iovchu, Communication Officer, UNFPA Moldova Mr Godfrey Walker, UNFPA International Expert</td>
</tr>
<tr>
<td>Time</td>
<td>Activity</td>
<td>Location</td>
<td>Participants</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Lunch time</td>
<td></td>
<td>Ms Eugenia Berzan, Programme Analyst RH and Youth, UNFPA Moldova</td>
</tr>
</tbody>
</table>
| 14:00-16:00| Meeting with Dr. Vera Munteanu, Manager of Health Center. Visiting the Health Center from Hîncești, including the Reproductive Health Office, Youth Friendly Health Center and a local pharmacy | Hîncești district 151, Mihalcea Hîncu Str. | Dr. Rita Columbia, UNFPA Representative in the Republic of Moldova  
Ms Ganna Iovchu, Communication Officer, UNFPA Moldova  
Mr Godfrey Walker, UNFPA International Expert  
Ms Eugenia Berzan, Programme Analyst RH and Youth, UNFPA Moldova  
Translator |
| 16:00-17:00| Departure to Chisinau                                                                          |                                  |                                                                                                 |
| 19.05.2017 (Friday) |                                                                                       |                                  |                                                                                                 |
| 9:00-10:00 | Meeting with Dr Haris Hajrulahovic, WHO Representative in the Republic of Moldova (as well as with Dr. Larisa Boderscova, National Professional Officer, Health Systems, WHO Moldova) | Chisinau 27, Sfatul Tarii Str.    | Dr. Rita Columbia, UNFPA Representative in the Republic of Moldova  
Ms Natalia Plugaru, Assistant Representative, UNFPA Moldova  
Dr Godfrey Walker, UNFPA International Expert  
Ms Eugenia Berzan, Programme Analyst RH and Youth |
| 10:30-11:30| Meeting with Ms Doina Munteanu, Assistant Resident Representative / Head of Programme, UNDP Moldova | Chisinau, 131, 31 August Str. UNFPA Office | Ms Natalia Plugaru, Assistant Representative, UNFPA Moldova  
Dr Godfrey Walker, UNFPA International Expert  
Ms Eugenia Berzan, Programme Analyst RH and Youth |
| 11:30-13:00| Lunch break                                                                                  |                                  |                                                                                                 |
| 13:00-14:00| Meeting with Ms Margarita Tileva, UNICEF Moldova Deputy Representative (as well as with Mrs Angela Capcelea, UNICEF Health Officer) | Chisinau, 131, 31 August Str. UNFPA Office | Ms Natalia Plugaru, Assistant Representative, UNFPA Moldova  
Dr Godfrey Walker, UNFPA International Expert  
Ms Eugenia Berzan, Programme Analyst RH and Youth |
| 14:00-17:30| Site visits to private pharmacies located in Chisinau Municipality (“Felicia”, “Hippocrates”, “Farmacia Familiei”, “Odeon”) |                                 | Mr Godfrey Walker, UNFPA International Expert  
Ms Victoria Dochitcu, Programme Associate RH and Youth, UNFPA Moldova  
Translator |
| 22.05.2017 (Monday) |                                                                                       |                                  |                                                                                                 |
| 9:30-10:30 | Meeting with Dr. Asia Odobescu, General Director of JV “RihPanGalFarma” LTD                  | Chisinau 36, N. Milescu Spataru Street | Dr. Rita Columbia, UNFPA Representative in the Republic of Moldova  
Ms Natalia Plugaru, Assistant Representative, UNFPA Moldova  
Mr Godfrey Walker, UNFPA International Expert  
Ms Eugenia Berzan, Programme Analyst RH and Youth, UNFPA Moldova  
Translator |
| 11:30-12:30| Meeting with Dr Elena Armașu, Executive Manager, “Bayer Pharmaceuticals” Office in the Republic of Moldova | Chisinau 196 Stefan cel Mare Blvd., 3rd floor | Dr. Rita Columbia, UNFPA Representative in the Republic of Moldova  
Ms Natalia Plugaru, Assistant Representative, UNFPA Moldova  
Mr Godfrey Walker, UNFPA International Expert |
<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Location</th>
<th>Facilitators</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30-14:00</td>
<td>Lunch break</td>
<td></td>
<td>Ms Eugenia Berzan, Programme Analyst RH and Youth, UNFPA Moldova Translator</td>
</tr>
<tr>
<td>14:00-17:30</td>
<td>Site visits to private pharmacies located in Chisinau Municipality (“Felicia”, “Hippocrates”, “Farmacia Familiei”, “Odeon” etc)</td>
<td>Chisinau Municipality</td>
<td>Mr Godfrey Walker, UNFPA International Expert Ms Victoria Dochitu, Programme Associate RH and Youth, UNFPA Moldova Translator</td>
</tr>
<tr>
<td>23.05.2017</td>
<td><strong>Tuesday</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00-10:00</td>
<td>Meeting with Prof. Olga Cernetchi Vice Rector, Head of Gynaecology Department of the State Medical and Pharmaceutical University “Nicolae Testemitanu”</td>
<td>Chisinau, 165, Stefan cel Mare si Sfint Blvd.</td>
<td>Ms Natalia Plugaru, Assistant Representative, UNFPA Moldova Mr Godfrey Walker, UNFPA International Expert Ms Eugenia Berzan, Programme Analyst RH and Youth Translator</td>
</tr>
<tr>
<td>10:30-11:30</td>
<td>Meeting with Prof. Ghenadie Curocchin Head of Family Medicine Department of the State Medical and Pharmaceutical University “Nicolae Testemitanu”</td>
<td>Chisinau, 137, 31 August 1989 Str. University Clinic of PHC</td>
<td>Ms Natalia Plugaru, Assistant Representative, UNFPA Moldova Dr Godfrey Walker, UNFPA International Expert Ms Eugenia Berzan, Programme Analyst RH and Youth, UNFPA Moldova Translator</td>
</tr>
<tr>
<td>11:30-13:00</td>
<td>Lunch break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-14:30</td>
<td>Meeting with Elena Robu, Deputy Director responsible for Mother and Child Health Care, Territorial Medical Association Centre</td>
<td>Chisinau, 63, 31 August Str.</td>
<td>Dr Godfrey Walker, UNFPA International Expert Ms Eugenia Berzan, Programme Analyst RH and Youth, UNFPA Moldova Translator</td>
</tr>
<tr>
<td>15:00-16:00</td>
<td>Meeting with Dr. Vera Melniciuc, Director of the “Dalila” Woman’s Health Center, Territorial Medical Association Botanica</td>
<td>Chisinau, 5/2 Dacia Bld.</td>
<td>Dr Godfrey Walker, UNFPA International Expert Ms Eugenia Berzan, Programme Analyst RH and Youth Translator</td>
</tr>
<tr>
<td>16:40-17:40</td>
<td>Meeting with Dr. Galina Leșco, Director of the “Neovita” Youth Friendly Health Center</td>
<td>Chisinau, 19, Socoleni Str.</td>
<td>Dr Godfrey Walker, UNFPA International Expert Ms Eugenia Berzan, Programme Analyst RH and Youth, UNFPA Moldova Translator</td>
</tr>
<tr>
<td>24.05.2017</td>
<td><strong>Wednesday</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00-10:30</td>
<td>Departure to Ungheni district</td>
<td>Ungheni district 27, Romana Str.</td>
<td>Ms Natalia Plugaru, Assistant Representative, UNFPA Moldova Mr Godfrey Walker, UNFPA International Expert Ms Eugenia Berzan, Programme Analyst RH and Youth, UNFPA Moldova Translator</td>
</tr>
<tr>
<td>10:30-12:30</td>
<td>Meeting with Dr. Lilia Scurtu, Manager of Health Center. Visiting the Health Center from Ungheni, including the Reproductive Health Office, Youth Friendly Health Center and a local pharmacy</td>
<td>Ungheni district 27, Romana Str.</td>
<td></td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>Lunch Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00-17:00</td>
<td>Meeting with Dr. Nicolae Lupu, Manager of Health Center. Visiting the Health Center from Călărași, including the Reproductive Health Office, Youth Friendly Health Center and a local pharmacy</td>
<td>Călărași district 1, Bojole Str.</td>
<td>Ms Natalia Plugaru, Assistant Representative, UNFPA Moldova Mr Godfrey Walker, UNFPA International Expert Ms Eugenia Berzan, Programme Analyst RH and Youth, UNFPA Moldova Translator</td>
</tr>
<tr>
<td>17:00-18:00</td>
<td>Departure to Chisinau</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**25.05.2017 (Thursday)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Location</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-10:00</td>
<td>Departure to Căușeni district</td>
<td></td>
<td>Dr. Rita Columbia, UNFPA Representative in the Republic of Moldova</td>
</tr>
<tr>
<td>10:00-12:00</td>
<td>Meeting with Dr. Valentina Panfilov, Manager of Health Center from Căușeni. Visiting the Health Center from Căușeni, including the Reproductive Health Office, Youth Friendly Health Center and a local pharmacy</td>
<td>Ana și Alexandru Str.</td>
<td>Mr Godfrey Walker, UNFPA International Expert, Ms Eugenia Berzan, Programme Analyst RH and Youth, UNFPA Moldova, Translator</td>
</tr>
<tr>
<td>12:00-13:00</td>
<td>Lunch Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00-16:30</td>
<td>Meeting with Dr. Nelli Buruian, Manager of Health Center. Visiting the Health Center from Anenii-Noi, including the Reproductive Health Office, Youth Friendly Health Center and a local pharmacy</td>
<td>Anenii-Noi district 30/1 Uzinelor Str.</td>
<td>Dr. Rita Columbia, UNFPA Representative in the Republic of Moldova, Mr Godfrey Walker, UNFPA International Expert, Ms Eugenia Berzan, Programme Analyst RH and Youth, UNFPA Moldova, Translator</td>
</tr>
<tr>
<td>17:00-17:45</td>
<td>Visiting the Health Center from Bulboaca village, Anenii-Noi district</td>
<td>Bulboaca village 43, M. Eminescu, Str.</td>
<td>Dr. Rita Columbia, UNFPA Representative in the Republic of Moldova, Mr Godfrey Walker, UNFPA International Expert, Ms Eugenia Berzan, Programme Analyst RH and Youth, UNFPA Moldova, Translator</td>
</tr>
<tr>
<td>17:45-18:30</td>
<td>Departure to Chisinau</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**26.05.2017 (Friday)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Location</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00-10:00</td>
<td>Departure to Costesti village, Ialoveni district</td>
<td></td>
<td>Mr Godfrey Walker, UNFPA International Expert, Ms Eugenia Berzan, Programme Analyst RH and Youth, UNFPA Moldova, Translator</td>
</tr>
<tr>
<td>10:00-11:30</td>
<td>Meeting with Manager of Health Center from Costesti and with Dr. Maria Bivol, Director of YFHC “Avante”. Visiting the Primary Healthcare Center from Costesti village, Ialoveni district, as well as YFHC “Avante” located in Costesti</td>
<td>Costesti village 7, Stefan cel Mare Str.</td>
<td>Mr Godfrey Walker, UNFPA International Expert, Ms Eugenia Berzan, Programme Analyst RH and Youth, UNFPA Moldova, Translator</td>
</tr>
<tr>
<td>12:00-13:30</td>
<td>Lunch Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-15:00</td>
<td>Debriefing Meeting at the UNFPA Moldova CO</td>
<td>Chisinau, 131, 31 August Str.</td>
<td>Dr. Rita Columbia, UNFPA Moldova Representative, Ms Natalia Plugaru, UNFPA Moldova Assistant Representative, Dr Godfrey Walker, UNFPA International Expert, Ms Eugenia Berzan, Programme Analyst RH and Youth, Ms Victoria Dochițcu, Programme Associate RH and Youth</td>
</tr>
</tbody>
</table>

**Departure of Dr. Godfrey Walker from Chisinau International Airport**

– 26/05.2017 W63797 KIV-LTN at 21:35 p.m.
Appendix 2: A series of pie charts showing the method mix for contraceptives used by women in 2012, by region of residence, urban and rural, woman’s age, number of living children, woman’s education level and wealth.
Urban

- Not using any method: 41.8%
- Female sterilisation: 13.6%
- IUD: 17.6%
- Pill: 7.8%
- Condom: 15.3%
- Diaphragm: 0.8%
- Any traditional method: 3%

Rural

- Not using any method: 39.7%
- Female sterilisation: 20.4%
- IUD: 8.2%
- Pill: 3.7%
- Condom: 22.6%
- Diaphragm: 5.2%
- Any traditional method: 0.1%
One living child

- Not using any method: 45%
- Female sterilisation: 17.1%
- IUD: 15.4%
- Pill: 5.1%
- Condom: 15.8%
- Diaphragm: 1.4%
- Any traditional method: 0%

Four living children

- Not using any method: 41.5%
- Female sterilisation: 24.5%
- IUD: 17%
- Pill: 0.8%
- Condom: 3.4%
- Diaphragm: 0.5%
- Any traditional method: 11.5%
Poorest 20 percent of women

- Not using any method: 44.5%
- Female sterilisation: 21.2%
- IUD: 19.3%
- Pill: 6.1%
- Condom: 5.9%
- Diaphragm: 2.7%
- Any traditional method: 0%

Richest 20 percent of women

- Not using any method: 38.7%
- Female sterilisation: 14.8%
- IUD: 14.9%
- Pill: 14.8%
- Condom: 8.9%
- Diaphragm: 3.2%
- Any traditional method: 0%